

Article

Gold-Catalyzed Hydroamination of Propargylic Alcohols: Controlling Divergent Catalytic Reaction Pathways to Access 1,3-Aminoalcohols, 3-Hydroxyketones or 3-Aminoketones

Victor Laserna, Michael J Porter, and Tom David Sheppard

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.9b00988 • Publication Date (Web): 16 Aug 2019

Downloaded from pubs.acs.org on August 17, 2019

Just Accepted


“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Gold-Catalyzed Hydroamination of Propargylic Alcohols: Controlling Divergent Catalytic Reaction Pathways to Access 1,3-Aminoalcohols, 3-Hydroxyketones or 3-Aminoketones.

Victor Laserna, Michael J. Porter and Tom D. Sheppard*

**Department of Chemistry, University College London, Christopher Ingold Laboratories, 20 Gordon Street, London, WC1H 0AJ, UK*

tom.sheppard@ucl.ac.uk




A versatile approach to the valorization of propargylic alcohols is reported, enabling controlled access to three different products from the same starting materials. Firstly, a general method for the hydroamination of propargylic alcohols with anilines is described using gold catalysis to give 3-hydroxyimines with complete regioselectivity. These 3-hydroxyimines can be reduced to give 1,3-aminoalcohols with high *syn* selectivity. Alternatively, by using a catalytic quantity of aniline, 3-hydroxyketones can be obtained in high yield directly from propargylic alcohols. Further manipulation of the reaction conditions enables the selective formation of 3-aminoketones via a rearrangement/hydroamination pathway. The utility of the new chemistry was exemplified by the one-pot synthesis of a selection of *N*-arylpyrrolidines and *N*-arylpiperidines. A mechanism for the hydroamination has been proposed on the basis of experimental studies and DFT calculations.

Introduction

Nitrogen atoms play a key role in many biologically active compounds including natural products and pharmaceuticals, and this has encouraged the development of new synthetic strategies to construct C-N bonds.¹ Hydroamination of alkenes or alkynes is an atom economical and direct method to generate C-N bonds which has attracted considerable interest.² Although alkenes yield amines directly, the transformation has often proved challenging. In contrast, the hydroamination of alkynes can be mediated by a range of catalysts based on elements from across the periodic table.^{2a,3} This offers an alternative strategy, yielding imines or enamines

which can be further transformed through sequential reactions to access useful products.⁴ Two key limitations of the hydroamination of alkynes are the low reactivity of internal alkynes and the poor regioselectivity usually observed with these substrates in intermolecular reactions (Scheme 1).⁵ Catalyst design has allowed improved regiocontrol for hydroamination of terminal alkynes, with late transition-metal catalysts usually affording Markovnikov products,⁶ whereas early transition-metal catalysts predominantly afford anti-Markovnikov products.^{3b,7} Internal alkyne hydroamination selectivity has proved to be more challenging, with reactions usually giving mixtures of isomers.⁵ A rare exception is the hydroamination of alkynes bearing strongly electron-withdrawing groups,⁸ which give high regioselectivities favoring amine attack on the more electron deficient atom of the π -system. The intermolecular hydroamination of internal alkynes using gold catalysts has been challenging, requiring elevated temperatures and yielding mixtures of isomeric products.^{5b,6a}

Scheme 1: Hydroamination of Alkynes




To date, the intermolecular hydroamination of propargylic alcohols to yield 3-hydroxyimines has not been reported, despite the potential utility of the products. The hydroamination of O-protected propargyl alcohol to give hydroxyacetone hydrazone derivatives has been described,^{9a} as well as the synthesis of benzodiazepines^{9b} or quinolines^{9c} via reaction of propargylic alcohols with nitrogen nucleophiles. In this paper, we describe a highly regioselective method for the hydroamination of propargylic alcohols under mild conditions, which can be controlled to provide three different products by varying the reaction conditions. This provides an unusual example of divergent catalysis¹⁰ which employs the same reactant and catalyst to access different products with high levels of selectivity.

Results and Discussion


Propargylic alcohols are readily available alkynes with an adjacent alcohol group which are versatile building blocks due to their diverse reactivity.¹¹ Through a wide array of different catalytic transformations, using transition metals¹² or organocatalysis,¹³ important synthetic targets can be accessed including enones,¹⁴ furans,¹⁵ carbonates,¹⁶ N-heterocycles¹⁷ or geminal dihalides.¹⁸ In a preliminary screen of conditions for hydroamination, we observed that reaction of propargylic alcohol **1a**, aniline and 2 mol% of $\text{PPh}_3\text{AuNTf}_2$ ¹⁹ catalyst at room temperature in CH_2Cl_2 led to complete conversion of starting material within 24 h (Scheme 2), with the formation of three products: 3-hydroxyimine **1b**, 3-hydroxyketone **1c** and 3-aminoketone **1d** in a ratio of 47:47:6 (**1b**:**1c**:**1d**).[‡] No traces of the regioisomeric products (α -hydroxyimine, α -hydroxyketone) resulting from an addition of the aniline to the proximal carbon of the propargylic alcohol were detected. We then decided to explore the reaction conditions to determine if it was possible to selectively obtain each of the three products.

Scheme 2 Initial Discovery of the Hydroamination Reaction




Synthesis of 1,3-Aminoalcohols

During the optimization process (Supporting information), we identified conditions to selectively generate the 3-hydroxyimine **1b** by performing the reaction in chloroform in the presence of molecular sieves. In order to trap the imine intermediate, we carried out a sequential reduction by adding Et_2O and 2 eq of NaCNBH_3 at 0 °C. As anticipated, we found that the reduction took place in a stereoselective manner yielding the *syn*-1,3-aminoalcohol in high yield and with excellent selectivity.²⁰

Scheme 3: Synthesis of *syn*-1,3-aminoalcohols via one-pot hydroamination/reduction of propargylic alcohols.


Reactions performed on a 0.5 mmol scale; Yields given are isolated yields of the *syn* diastereoisomer (stereochemistry shown in reaction assumes R³ is smaller than R²); (PMP = *p*-methoxyphenyl); ^aThe relative stereochemistry was confirmed by conversion to the corresponding cyclic urethane and analysis of the NOESY spectra (Supporting Information).

We examined a series of different anilines to explore the functional group tolerance of the method (Scheme 3).[‡] The reaction tolerates a variety of substitution patterns on the aniline, with groups at the *ortho* (**1bg** and **1bh**), *meta* (**1bc**, **1be** and **1bf**) or *para* (**1bb** and **1bd**) position, with slightly lower yields observed in the first case probably due to steric hindrance. Electron withdrawing groups (**1bb**, **1be**, **1bf** and **1bh**) and electron donating groups (**1bc**, **1bd** and **1bg**) are well tolerated. No hydroamination was observed with alkylamines, presumably because they cause greater deactivation of the cationic gold catalyst.²¹ A range of substrates including primary (**7ba**), secondary (**3ba**, **5ba**, **8ba**, **9bd**), tertiary (**2ba**, **4ba**, **6ba**) and benzylic (**3ba**, **4ba**) propargylic alcohols can be transformed into the corresponding amino alcohols effectively. Terminal alkynes did not undergo hydroamination when subjected to the reaction conditions, and only unreacted starting material was observed with these substrates. We were also able to access a primary aminoalcohol **1bi** by oxidative deprotection of *p*-methoxyphenylamine **1bd** using trichloroisocyanuric acid (Scheme 4).²²

Scheme 4: Synthesis of a primary aminoalcohol via deprotection of a *p*-methoxyphenylamine (PMP = *p*-methoxyphenyl; TCCA = trichloroisocyanuric acid).

Synthesis of 3-Hydroxyketones

During the optimization of the hydroamination reaction we observed that raising the temperature and performing the reaction in non-dried solvents under air favoured the hydrolysis of the imine to yield the 3-hydroxyketone. We hypothesized that *in situ* imine hydrolysis would liberate the aniline, allowing it to participate in further hydroamination reactions. It should therefore be possible to achieve the reaction with a substoichiometric quantity of amine. After examining a small selection of anilines in combination with the gold catalyst (Supporting information), 3-trifluoromethylaniline was identified as a suitable co-catalyst to promote formation of the 3-hydroxyketone. The proposed hydroamination/imine hydrolysis pathway is supported by the fact that in the absence of aniline, Meyer-Schuster rearrangement of the propargylic alcohol is predominant and only small quantities of 3-hydroxyketone are formed.^{14a, 23} With these conditions in hand we explored the scope of the hydroamination/hydrolysis reaction for preparing 3-hydroxyketones (Scheme 5). The reaction tolerates a range of substituents on the propargylic alcohol, including carbocycles (**2c**, **14c**, **17c** and **23c**) and branched chains (**9c**, **13c**), and is compatible with primary (**7c** and **20c**), secondary (**1c**, **3c**, **5c**, **9c-17c**, **19c**, **21c**, **23c-26c**, **28c**, **29c**), tertiary (**2c**, **4c**, **6c**, **18c**, **22c** and **27c**) and benzylic (**3c**, **4c**, **9c**, **11c**, **12c**, **17c**, **21c**, **24c** and **26c**) propargylic alcohols, even though the latter products are often prone to elimination of water to give the corresponding enones.²³ Electron withdrawing (cyano: **24c**, nitro: **16c**, halide: **3c/17c**) or electron donating (methoxy: **10c**, methyl: **21c**) substituents could be present on the benzene rings, and alternative aromatic systems such as furan (**11c**), naphthalene (**26c**) or thiophene (**12c**) were also tolerated, as were alkenes (**27c**), protected alcohols (**27c**), esters (**28c**) and acetals (**6c**, **23c**, **25c** and **29c**).

Scheme 5 Synthesis of 3-hydroxyketones via catalytic hydroamination of propargylic alcohols with in situ imine hydrolysis.

Reactions performed on a 0.5 mmol scale; Undried solvents were used for these reactions; (PMP = *p*-methoxyphenyl; PNP = *p*-nitrophenyl). ^aIn other solvents, the yields of **1c** obtained were as follows: MeCN (88%), PhF (86%), MeOCO₂Me (85%), PhMe (88%), EtOAc (82%); ^b 5 mmol scale reaction; ^c 0.5 eq of aniline used; ^d Reaction carried out at room temperature for 40 h.


The broad scope of this method for the synthesis of 3-hydroxyketones makes it a useful alternative approach to traditional approaches such as aldol reactions.²⁴ As chlorinated solvents are often undesirable from an environmental perspective, we examined the reaction in alternative solvents.²⁵ Pleasingly, the hydroamination/hydrolysis reaction could also be performed efficiently in acetonitrile, fluorobenzene, dimethyl carbonate, toluene or ethyl acetate.

Synthesis of 3-Aminoketones

Finally, we also sought to develop conditions to access the 3-aminoketone **1d**, which was identified as a minor product in our original experiment (Scheme 2). We hypothesized that its formation was due to Meyer-Schuster rearrangement of the propargylic alcohol,¹⁴ followed by conjugate addition of the aniline to the resulting enone. To selectively form the 3-aminoketone, we changed the solvent to a mixture of toluene:MeOH (100:1) which is established to promote gold-catalyzed Meyer-Schuster rearrangement,¹⁴ and then added the aniline to the reaction mixture once the enone had been produced (Scheme 6). Interestingly, the gold catalyst is involved in both steps of the reaction, as it was observed to catalyze conjugate addition of the aniline to the enone (Supplementary information), with a particularly significant effect in the case of less nucleophilic anilines. Whilst the addition of anilines to

electron-deficient alkenes can be mediated by a variety of catalysts,²⁶ this gold-catalysed variant appears to be complementary in scope as previous reports have not included internal enones as substrates.²⁶

Scheme 6: Synthesis of 3-aminoketones via Au-catalyzed Meyer-Schuster rearrangement and enone hydroamination.




Reactions performed on a 0.5 mmol scale; (a) Reaction was filtered through a silica pad after enone formation; (b) The corresponding enone was obtained as the sole product.

Again, we examined the reaction with a series of different aryl amines on substrate **1a**, and explored the functional group tolerance with respect to the propargylic alcohol component using aniline as the nucleophile (Scheme 6). Although the reaction proved to be tolerant of both electron-deficient and electron-rich anilines (**1da-1dj**), only primary (**7da**) and secondary (**5da**, **14da**, **25da**) propargylic alcohols were suitable substrates. While tertiary and benzylic alcohols underwent the Meyer-Schuster rearrangement, no conjugate addition to the resulting enone to give **18da** or **19da** was observed.

Reaction Mechanisms


Several gold-catalysed reactions of allylic alcohols with nucleophiles have been reported which proceed via a mechanism in which addition of the nucleophile is concerted with elimination of the adjacent hydroxyl group.²⁷ In order to exclude the possibility that the hydroamination of propargylic alcohols proceeds in a similar fashion via a planar achiral intermediate (e.g. via Meyer-Schuster rearrangement), we examined the reaction of enantioenriched alcohol (**S**)-**9a**.²⁸ Pleasingly, alcohol (**S**)-**9a** could be converted into hydroxyketone (**S**)-**9c** in excellent yield and with no significant loss in enantiopurity (Scheme 7). Similarly, hydroamination followed by imine reduction gave the corresponding aminoalcohol in 72% yield as an 85:15 mixture of diastereomers. We were unable to directly determine the enantiopurity of the diastereomeric product mixture by HPLC, so recrystallisation was carried out, affording the aminoalcohol (**1S,3R**)-**9bd** as an essentially enantiopure single diastereomer in 59% overall yield (Scheme 7). As analysis of the crude mixture had indicated that only 61% of this diastereomer was present (i.e. 0.85×72), it could be concluded that the hydroamination reaction and reduction had taken place without any significant erosion of enantiomeric purity.

Scheme 7: Synthesis of enantioenriched products via hydroamination of an enantioenriched propargylic alcohol.



The alcohol moiety in the propargylic alcohol appears to play an important role in accelerating the hydroamination reaction (Scheme 8), as a competition experiment between propargylic alcohol **1a** and hex-3-yne illustrates (A). Protection of the propargylic alcohol as a benzyl or trimethylsilyl ether appears to stop the hydroamination reaction (B).

Scheme 8: Experiments to probe the relative reactivity of propargylic alcohols in the hydroamination reaction in comparison to other alkyne derivatives.




In order to investigate the reaction mechanism further, DFT calculations were carried out. Several computational studies into both inter-²⁹ and intramolecular³⁰ hydroamination reactions catalysed by mononuclear gold complexes have been reported previously; we chose to employ the benchmarked method of Ciancaleoni et al.^{29c} in which single-point energies are calculated using the hybrid B2PLYP functional³¹ on geometries optimized using the GGA functional BP86,³² with the def2-TZVPP basis set³³ being used throughout. Solution-phase energies were obtained using the SMD solvation model³⁴ with gas-phase optimized geometries. All calculations were carried out using Gaussian 09.³⁵

Initial modelling of but-2-yn-1-ol complexed to an $[\text{Au-PMe}_3]^+$ fragment indicated that the gold-alkyne complex was slightly lower in energy than a structure with the gold linked to the alcohol oxygen. Transition states were then modelled for addition of aniline to each carbon of the triple bond in this adduct. The transition state for addition to the distal carbon (Figure 1), as observed experimentally, lay only 9.9 kJ mol⁻¹ higher in energy than the isolated starting materials, with a hydrogen bond between the aniline N-H and the alcohol oxygen. Conversely, the transition state for addition to the proximal carbon was markedly higher in energy (31.1 kJ mol⁻¹ above starting materials).

The condensed Fukui functions³⁶ f_k^+ for these two carbons in the initial gold complex were found to be respectively 0.063 and 0.055 indicating only a small difference in the intrinsic electrophilicity of the two sites. Distortion-interaction analysis³⁷ (see supporting information) suggested that both potential addition pathways involved similar energetic costs in distorting the starting materials, with the difference between the pathways arising from the more favourable interaction energy for attack at the distal carbon. We tentatively assign this difference to a stronger hydrogen-bonding interaction in the


distal attack, due to a more linear geometry for the hydrogen bond in the incipient six-membered ring: at the transition state for distal attack, the O-H-N angle is 145.6° while the corresponding angle for proximal attack is 125.6° .

Figure 1: Transition states for addition of aniline to the distal (left) and proximal (right) carbon atoms of a but-2-yn-1-ol/Au-PMe₃ cationic complex, calculated at the B2PLYP/def2TZVPP//BP86/def2TZVPP level.³⁸



For the corresponding addition of aniline to an unfunctionalized alkyne (but-2-yne), the energy barrier was higher still (37.7 kJ mol^{-1} above starting materials), indicating that the hydroxyl substituent plays a role in facilitating the addition reaction as well as determining its regioselectivity.

Scheme 9: Plausible reaction mechanisms for the formation of the three different products. The diastereoselectivity shown assumes R^2 is larger than R^3 .




These considerations lead us to suggest the mechanisms shown in Scheme 9. Thus, gold-catalysed addition of the aniline to the complexed alkyne (**B**) is assisted by hydrogen bonding of the aniline to the oxygen lone pair, and this hydrogen bond also controls the regioselectivity of the addition step. After protodeauration of vinylgold intermediate **C**, the resulting enamine **D** can tautomerise to the imine **E** which undergoes hydrolysis to yield the hydroxyketone when water is present (path 1). Under anhydrous conditions, the imine is stable and can be subsequently reduced to the *syn* amino-alcohol (path 2). Further support for these two pathways was obtained from NMR analysis of a reaction of propargylic alcohol **18a** with 0.5 equivalents of 3-trifluoromethylaniline in the presence of PPh₃AuNTf₂

which showed a mixture of 3-hydroxyimine **E** and 3-hydroxyketone **18c** (Supporting Information). The aminoketone product is generated via hydroamination of the enone **F** which is formed readily via Meyer-Schuster rearrangement under conditions similar to those we have previously reported (path 3).¹⁴

Synthesis of Nitrogen Heterocycles

In order to demonstrate the synthetic potential of the hydroamination reaction, we synthesised a small selection of *N*-arylpyrrolidines/piperidines from the corresponding acetal-containing propargylic alcohols (Scheme 10). We were able to find suitable conditions under which the acetal-containing aminoalcohol was selectively transformed into the pyrrolidine/piperidine product using trifluoroacetic acid and NaBH₄. Pleasingly, the heterocycle synthesis could be performed without the need to purify any of the intermediate aminoalcohol compounds.

Scheme 10: Synthesis of *N*-arylpyrrolidines and *N*-arylpyrrolidines via one-pot gold-catalysed hydroamination of propargylic alcohols, followed by reduction and reductive amination. Yields shown are for the isolated product after the three step sequence.



Conclusions

In conclusion, we report a method for the valorization of propargylic alcohols through gold catalysed hydroamination.³⁹ In the presence of an aniline and a commercially available gold catalyst, propargylic alcohols undergo regioselective hydroamination yielding a 3-hydroxyimine which can be stereoselectively reduced to a *syn*-1,3-aminoalcohol or hydrolyzed to the corresponding 3-hydroxyketone. By changing to a two-step one-pot process, 3-aminoketones can be obtained via Meyer-Schuster rearrangement and conjugate addition of the aniline to the resulting enone. The latter step is formally a hydroamination of the enone, which is also catalysed by gold. Thus, by using the same substrates and catalyst under different conditions, three different products can be obtained efficiently with high selectivity. This constitutes a highly unusual divergent catalytic reaction.

Experimental Section

General Experimental Procedures

All solvents and chemicals were used as received. Column chromatography was carried out using either Merck Geduran Si 60 (40-63 μm) silica gel or a Biotage purification system using Biotage columns. Analytical thin layer chromatography was carried out using Merck TLC Silica Gel 60 F₂₅₄ aluminium-backed plates. Components were visualised using combinations of ultra-violet lights and potassium permanganate.

Proton magnetic resonance spectra (^1H NMR) were recorded at 400, 500 or 600 MHz on a Bruker Avance spectrometer and are reported as follows: chemical shift δ in ppm (number of protons, multiplicity, coupling constant J in Hz, assignment). The solvent used was deuterated chloroform unless stated otherwise. Residual protic solvent was used as the internal reference, setting CHCl_3 to δ 7.26. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad or a combination of these. Carbon magnetic resonance spectra (^{13}C NMR) were recorded at 100, 125 or 150 MHz on a Bruker Avance spectrometer using deuterated chloroform using the central reference of CDCl_3 to δ 77.0 as the internal standard. Mass Spectrometry data were collected on either TOF or magnetic sector analysers at the Department of Chemistry, University College London. The ionization method is reported in the experimental data.

Preparation of propargylic alcohols

n-Butyllithium (1.6 M in hexanes, 1.2 eq., 3.75 mL) was added dropwise to a stirred solution of the corresponding alkyne (5 mmol) in anhydrous THF (25 mL) at -78°C under an argon atmosphere. After 30 min aldehyde (1 eq.) was added and the resulting solution was stirred for 5 min at 0°C and then 30 min at rt. The reaction was diluted with aq. saturated NH_4Cl and the organic phase extracted with Et_2O . The combined organic phases were washed with brine, dried (MgSO_4), filtered and concentrated *in vacuo*. The residue was purified by column chromatography (EtOAc/Petrol) to give the propargylic alcohol.

The aldehyde used to prepare propargylic alcohol **8a** was synthesized following reported procedures.⁴⁰ Alkynes used to prepare **6a**, **23a**, **25a**, **26a**, **27a**, **28a**, **29a** and **30a** were synthesized following reported procedures.⁴¹

Propargylic alcohols **7a** and **20a** were purchased from commercial suppliers. We have previously reported the synthesis of propargylic alcohols **9a**,^{18a} **17a**,^{18a} **21a**,^{18a} **22a**,²³ and **29a**.^{18b} Enantioenriched propargylic alcohol (**S**)-**9a** (e.r. 96:4) was synthesized following reported procedures.^{23,28}

Tridec-5-yn-7-ol (**1a**)⁴²

891 mg, 91%, colourless oil, ^1H NMR (600 MHz, CDCl_3) δ 4.34 (tt, $J = 6.4, 1.9$ Hz, 1H), 2.22 (td, $J = 7.0, 2.0$ Hz, 2H), 1.75–1.58 (m, 2H), 1.53–1.45 (m, 2H), 1.46–1.36 (m, 4H), 1.36–1.22 (m, 6H), 0.91 (t, $J = 7.2$ Hz, 3H), 0.89 (t, $J = 7.3$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 85.6, 81.5, 62.9, 38.3, 31.9, 30.86, 29.1, 25.3, 22.7, 22.0, 18.5, 14.2, 13.7. IR ν_{max} (solid/ cm^{-1}) 3353 (O-H), 2955 (C-H), 2927 (C-H), 2858 (C-H), 1506, 1431, 1145, 1039, 726.

1-(Hex-1-ynyl)cyclohexan-1-ol (**2a**)⁴³

774 mg, 86%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 2.20 (t, $J = 9.5$, 2H), 1.99 (br s, 1H), 1.83 (m, 2H), 1.70–1.61 (m, 2H), 1.58–1.44 (m, 7H), 1.44–1.34 (m, 2H), 1.25–1.18 (m, 1H), 0.89 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 84.8, 84.0, 68.9, 40.4, 31.0, 25.4, 23.57, 22.0, 18.4, 13.7. IR ν_{max} (solid/ cm^{-1}) 3484 (O-H), 2931 (C-H), 2858 (C-H), 1447, 1340, 1056, 961, 752.

1-(2-Chlorophenyl)hept-2-yn-1-ol (3a)⁴⁴

987 mg, 89%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.76 (dd, $J = 7.7$, 1.7 Hz, 1H), 7.37 (dd, $J = 7.9$, 1.3 Hz, 1H), 7.31 (td, $J = 7.5$, 1.3 Hz, 1H), 7.28–7.24 (m, 1H), 5.81 (s, 1H), 2.35 (m, 1H), 2.27 (td, $J = 7.1$, 2.1 Hz, 2H), 1.57–1.47 (m, 2H), 1.46–1.37 (m, 2H), 0.91 (t, $J = 7.3$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 138.6, 132.9, 129.8, 129.6, 128.5, 127.3, 88.0, 78.9, 62.3, 30.7, 22.1, 18.6, 13.7. IR ν_{max} (solid/ cm^{-1}) 3351 (O-H), 2957 (C-H), 2931 (C-H), 2871 (C-H), 1467, 1442, 1052, 1035, 750.

2-(4-Chlorophenyl)hex-3-yn-2-ol (4a)⁴⁵

898 mg, 77%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.58 (m, 2H), 7.31 (m, 2H), 2.27 (m, 2H), 1.71 (s, 3H), 1.58–1.48 (m, 2H), 1.50–1.37 (m, 2H), 0.92 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 144.9, 133.4, 128.4, 126.6, 86.2, 83.5, 69.7, 33.8, 30.8, 22.1, 18.5, 13.7. IR ν_{max} (solid/ cm^{-1}) 3425 (O-H), 2995 (C-H), 2933 (C-H), 2889 (C-H), 1497, 1371, 1025, 819.

1-Phenylnon-1-yn-3-ol (5a)⁴⁶

960 mg, 89%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.45–7.41 (m, 2H), 7.34–7.28 (m, 3H), 4.60 (t, $J = 6.5$ Hz, 1H), 1.92 (br s, 1H), 1.84–1.76 (m, 2H), 1.56–1.47 (m, 2H), 1.40–1.34 (m, 2H), 1.35–1.25 (m, 4H), 0.93–0.86 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 131.8, 128.5, 128.4, 122.8, 90.4, 85.0, 63.2, 38.1, 31.9, 29.1, 25.32, 22.7, 14.2. IR ν_{max} (solid/ cm^{-1}) 3366 (O-H), 2927 (C-H), 2857 (C-H), 1489, 1457, 1062, 755, 690.

7,7-Diethoxy-2-methylhept-3-yn-2-ol (6a)

834 mg, 78%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.57 (t, $J = 5.7$ Hz, 1H), 3.64 (dq, $J = 9.3$, 7.1 Hz, 2H), 3.49 (dq, $J = 9.4$, 7.1 Hz, 2H), 2.24 (t, $J = 7.3$ Hz, 2H), 2.12 (br s, 1H), 1.78 (m, 2H), 1.47 (s, 6H), 1.19 (t, $J = 7.1$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 101.8, 85.5, 81.7, 65.2, 61.5, 32.8, 31.8, 15.4, 14.3. IR ν_{max} (solid/ cm^{-1}) 3429 (O-H), 2975 (C-H), 2930 (C-H), 2875 (C-H), 1456, 1373, 1127, 1056, 949. HRMS (ESI-TOF) m/z : $[\text{M}+\text{NH}_4]^+$ Calcd for $\text{C}_{12}\text{H}_{26}\text{O}_3\text{N}^+$, 232.1907; Found, 232.1907.

5,5-Diethoxy-1-phenylpent-1-yn-3-ol (8a)

892 mg, 72%, yellow oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.46–7.36 (m, 2H), 7.33–7.28 (m, 3H), 4.93 (t, $J = 5.7$ Hz, 1H), 4.79 (t, $J = 5.5$ Hz, 1H), 3.87–3.68 (m, 2H), 3.59 (m, 2H), 3.40 (br s, 1H), 2.20–2.10 (m, 2H), 1.25 (t, $J = 7.1$ Hz, 3H), 1.23 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 131.7, 128.4, 128.3, 122.7, 101.5, 89.4, 84.8, 62.5, 61.9, 60.0, 40.6, 15.4, 15.4. IR ν_{max} (solid/ cm^{-1}) 3412 (O-H), 2974 (C-H), 2930 (C-H), 2882 (C-H), 1489, 1374, 1119, 1049, 755, 690, 829. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{15}\text{H}_{20}\text{O}_3\text{Na}^+$, 271.1305; Found, 271.1305.

1-(4-Methoxyphenyl)hept-2-yn-1-ol (10a)⁴²

1021 mg, 94%, colourless oil, ¹H NMR (600 MHz, CDCl₃) δ 7.58–7.38 (m, 2H), 6.95–6.86 (m, 2H), 5.40 (s, 1H), 3.81 (s, 3H), 2.27 (td, *J* = 7.1, 2.0 Hz, 2H), 2.15 (br s, 1H), 1.62–1.49 (m, 2H), 1.47–1.32 (m, 2H), 1.01–0.83 (m, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 159.7, 133.8, 128.2, 114.0, 87.6, 80.2, 64.6, 55.5, 30.8, 22.1, 18.6, 13.7. IR ν_{max} (solid/cm⁻¹) 3403 (O-H), 2956 (C-H), 2932 (C-H), 2836 (C-H), 1610, 1509, 1244, 1171, 1031, 634.

1-(Furan-2-yl)hept-2-yn-1-ol (11a)^{14b}

703 mg, 79%, colourless oil, ¹H NMR (600 MHz, CDCl₃) δ 7.41–7.35 (m, 1H), 6.42 (br d, *J* = 3.2 Hz, 1H), 6.34 (dd, *J* = 3.2, 1.8 Hz, 1H), 5.43 (s, 1H), 2.32–2.28 (m, 1H), 2.27 (td, *J* = 7.1, 2.1 Hz, 2H), 1.57–1.48 (m, 2H), 1.41 (m, 2H), 0.96–0.88 (m, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 153.9, 143.0, 110.4, 107.5, 87.0, 77.6, 58.5, 30.6, 22.1, 18.6, 13.7. IR ν_{max} (solid/cm⁻¹) 3396 (O-H), 2957 (C-H), 2932 (C-H), 2872 (C-H), 1501, 1148, 1005, 735, 598.

1-(Thiophen-2-yl)hept-2-yn-1-ol (12a)⁴⁷

896 mg, 93%, brown oil, ¹H NMR (600 MHz, CDCl₃) δ 7.27 (dd, *J* = 5.1, 1.1 Hz, 1H), 7.16–7.13 (m, 1H), 6.98–6.94 (m, 1H), 5.62 (s, 1H), 2.35 (br s, 1H), 2.28 (td, *J* = 7.1, 2.0 Hz, 2H), 1.63–1.50 (m, 2H), 1.50–1.39 (m, 2H), 0.92 (t, *J* = 7.3 Hz, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 145.8, 126.8, 125.9, 125.4, 87.2, 79.7, 60.5, 30.7, 22.1, 18.6, 13.7. IR ν_{max} (solid/cm⁻¹) 3381 (O-H), 2956 (C-H), 2933 (C-H), 2877 (C-H), 906, 728, 698.

2-Methylnon-4-yn-3-ol (13a)⁴²

692 mg, 90%, colourless oil, ¹H NMR (600 MHz, CDCl₃) δ 4.14 (dt, *J* = 5.5, 2.0 Hz, 1H), 2.20 (td, *J* = 7.0, 2.0 Hz, 2H), 1.87–1.79 (m, 1H), 1.55–1.46 (m, 2H), 1.44–1.31 (m, 2H), 0.98 (d, *J* = 6.7 Hz, 3H), 0.95 (d, *J* = 6.7 Hz, 3H), 0.90 (t, *J* = 7.3 Hz, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 86.3, 79.9, 68.3, 68.2, 34.8, 34.8, 30.9, 22.0, 18.5, 18.2, 18.2, 17.5, 17.5, 13.7. IR ν_{max} (solid/cm⁻¹) 3383 (O-H), 2958 (C-H), 2931 (C-H), 2872 (C-H), 1671, 1466, 1381, 1049, 1021, 779.

1-Cyclohexylhept-2-yn-1-ol (14a)⁴²

843 mg, 87%, colourless oil, ¹H NMR (600 MHz, CDCl₃) δ 4.15–4.09 (m, 1H), 2.26–2.17 (m, 2H), 1.82 (d, *J* = 12.3 Hz, 2H), 1.75 (d, *J* = 12.6 Hz, 2H), 1.70–1.60 (m, 1H), 1.52–1.44 (m, 3H), 1.45–1.36 (m, 2H), 1.28–1.19 (m, 2H), 1.19–1.09 (m, 2H), 1.09–1.00 (m, 1H), 0.96–0.85 (m, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 86.4, 80.2, 67.6, 44.5, 30.9, 28.7, 28.2, 26.6, 26.0, 22.1, 18.5, 13.7. IR ν_{max} (solid/cm⁻¹) 3345 (O-H), 2923 (C-H), 2852 (C-H), 1449, 1008, 892.

Docosa-8,14-diyne-7,16-diol (15a)

1068 mg, 62%, colourless oil, mixture of diastereoisomers (1:1). ^1H NMR (600 MHz, CDCl_3) δ 4.31 (m, 2H), 2.28–2.18 (m, 4H), 1.64 (m, 4H), 1.59–1.56 (m, 4H), 1.46–1.36 (m, 4H), 1.31–1.22 (m, 12H), 0.89–0.83 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 84.9, 81.9, 62.79 (*diastereomer 1*), 62.78 (*diastereomer 2*) 38.3, 31.9, 29.1, 27.8, 25.3, 22.7, 18.3, 14.2. IR ν_{max} (solid/ cm^{-1}) 3355 (O-H), 2926 (C-H), 2857 (C-H), 1458, 1329, 1039, 735. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{37}\text{O}_2^+$, 333.2788; Found, 333.2785.

1-(4-Nitrophenyl)-5-phenylpent-2-yn-1-ol (16a)⁴⁸

1231 mg, 88%, colourless oil, ^1H NMR (600 MHz, CDCl_3) δ 8.27–8.10 (m, 2H), 7.64–7.50 (m, 2H), 7.33–7.28 (m, 2H), 7.27–7.22 (m, 1H), 7.20 (dd, $J = 7.8, 0.9$ Hz, 2H), 5.56–5.45 (m, 1H), 2.85 (t, $J = 7.4$ Hz, 2H), 2.60 (td, $J = 7.4, 2.0$ Hz, 2H), 2.33 (d, $J = 5.8$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 147.9, 147.8, 140.3, 128.6, 127.5, 127.4, 126.6, 123.8, 88.1, 80.0, 63.9, 34.7, 20.9. IR ν_{max} (solid/ cm^{-1}) 3405 (O-H), 3029 (C-H), 2930 (C-H), 1519 (C=C), 1343, 1265, 1011, 732, 697.

3-Ethylnon-4-yn-3-ol (18a)⁴⁹

695 mg, 83%, colourless oil, ^1H NMR (600 MHz, CDCl_3) δ 2.18 (m, 2H), 1.98 (br s, 1H, OH), 1.61 (m, 4H), 1.51–1.41 (m, 2H), 1.39 (m, 2H), 0.99 (t, $J = 7.20$ Hz, 6H), 0.88 (t, $J = 7.30$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 84.9, 82.7, 72.3, 34.7, 31.0, 22.0, 18.4, 13.7, 8.7. IR ν_{max} (solid/ cm^{-1}) 3341 (O-H), 2993 (C-H), 2933 (C-H), 2852 (C-H), 1459, 1019, 871.

1-Phenylhept-2-yn-1-ol (19a)⁴²

801 mg, 85%, colourless oil, ^1H NMR (600 MHz, CDCl_3) δ 7.59–7.52 (m, 2H), 7.38 (m, 2H), 7.35–7.32 (m, 1H), 5.45 (s, 1H), 2.34–2.25 (m, 2H), 1.56–1.51 (m, 2H), 1.47–1.40 (m, 2H), 0.92 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 141.4, 128.7, 128.3, 126.8, 87.8, 80.0, 65.0, 30.8, 22.1, 18.6, 13.7. IR ν_{max} (solid/ cm^{-1}) 3362 (O-H), 2957 (C-H), 2931 (C-H), 2871 (C-H), 1641, 1497, 1314, 999, 696.

1-Cyclohexyl-6,6-diethoxyhex-2-yn-1-ol (23a)

1045 mg, 79%, colourless oil, ^1H NMR (400 MHz, CDCl_3) δ 4.60 (t, $J = 5.7$ Hz, 1H), 4.12 (d, $J = 5.9$ Hz, 1H), 3.66 (dq, $J = 9.4, 7.1$ Hz, 2H), 3.51 (dq, $J = 9.4, 7.1$ Hz, 2H), 2.30 (td, $J = 7.3, 2.0$ Hz, 2H), 1.88–1.80 (m, 4H), 1.78 (s, 1H), 1.71–1.64 (m, 2H), 1.56–1.47 (m, 1H), 1.33–0.97 (m, 12H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 101.8, 85.43, 80.5, 67.5, 61.6, 44.4, 32.9, 28.7, 28.2, 26.5, 25.98, 25.95, 15.4, 14.5. IR ν_{max} (solid/ cm^{-1}) 3382 (O-H), 2973 (C-H), 2924 (C-H), 2852 (C-H), 1448, 1374, 1118, 1056, 731. HRMS (ESI-TOF) m/z : $[\text{M}+\text{NH}_4]^+$ Calcd for $\text{C}_{16}\text{H}_{32}\text{O}_3\text{N}^+$, 286.2377; Found, 286.2376.

4-(1-Hydroxyhept-2-yn-1-yl)benzonitrile (24a)⁵⁰

902 mg, 84%, colourless oil, ^1H NMR (600 MHz, CDCl_3) δ 7.72–7.60 (m, 4H), 5.49 (s, 1H), 2.35 (s, 1H), 2.26 (td, $J = 7.1, 2.1$ Hz, 2H), 1.62–1.46 (m, 2H), 1.50–1.34 (m, 2H), 0.97–0.84 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151

MHz, CDCl₃) δ 146.4, 132.5, 127.3, 118.8, 112.0, 88.9, 79.1, 64.1, 30.6, 22.1, 18.6, 13.7. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3402 (O-H), 2957 (C-H), 2932 (C-H), 2871 (C-H), 2229 (CN) 1608, 1463, 1325, 1134 1013, 887, 562.

1,1-Diethoxydodec-4-yn-6-ol (25a)

952 mg, 71%, colourless oil. **¹H NMR** (400 MHz, CDCl₃) δ 4.59 (t, J = 5.7 Hz, 1H), 4.33 (m, 1H), 3.75–3.60 (m, 2H), 3.58–3.45 (m, 2H), 2.28 (td, J = 7.3, 1.9 Hz, 2H), 1.81 (m, 2H), 1.65 (m, 2H), 1.48–1.38 (m, 2H), 1.40–1.27 (m, 6H), 1.20 (t, J = 7.1 Hz, 6H), 0.88 (t, J = 6.8 Hz, 3H). **¹³C{¹H} NMR** (151 MHz, CDCl₃) δ 101.8, 84.6, 81.8, 62.8, 61.6, 38.3, 32.8, 31.9, 29.1, 25.3, 22.7, 15.4, 14.5, 14.2. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3418 (O-H), 2956 (C-H), 2928 (C-H), 2858 (C-H), 1445, 1375, 1127, 1059. **HRMS** (ESI-TOF) m/z : [M+NH₄]⁺ Calcd for C₁₆H₃₄O₃N⁺, 288.2533; Found, 288.2533.

1-(Naphthalen-1-yl)hept-2-yn-1-ol (26a)⁵¹

954 mg, 80%, colourless oil **¹H NMR** (400 MHz, CDCl₃) δ 8.33 (d, J = 8.5 Hz, 1H), 7.99–7.80 (m, 3H), 7.63–7.43 (m, 3H), 6.20–6.06 (m, 1H), 2.36 (d, J = 5.7 Hz, 1H), 2.31 (td, J = 7.1, 3.7 Hz, 2H), 1.67–1.50 (m, 2H), 1.49–1.36 (m, 2H), 0.93 (t, J = 7.3 Hz, 3H). **¹³C{¹H} NMR** (151 MHz, CDCl₃) δ 136.4, 134.2, 130.7, 129.3, 128.8, 126.4, 125.9, 125.4, 124.6, 124.2, 88.5, 79.8, 63.21, 30.8, 22.1, 18.7, 13.7. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3367 (O-H), 3049, 2956 (C-H), 2930 (C-H), 2870 (C-H), 1687, 1573, 1104, 774.

9-((*tert*-Butyldimethylsilyl)oxy)-5-methylnon-1-en-6-yn-5-ol (27a)

944 mg, 67%, colourless oil, **¹H NMR** (600 MHz, CDCl₃) δ 5.87 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.06 (dq, J = 17.1, 1.7 Hz, 1H), 4.97 (dq, J = 10.2, 1.3 Hz, 1H), 3.70 (t, J = 7.1 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), 2.35–2.21 (m, 2H), 1.79–1.67 (m, 2H), 1.46 (s, 3H), 0.93–0.88 (s, 9H), 0.09–0.04 (s, 6H). **¹³C{¹H} NMR** (151 MHz, CDCl₃) δ 138.6, 114.8, 84.8, 81.2, 68.3, 62.0, 42.9, 30.3, 29.4, 26.0, 23.2, 18.4, -5.2. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3397 (O-H), 2953 (C-H), 2929 (C-H), 2857 (C-H), 1641, 1470, 1274, 1103, 909, 834, 775. **HRMS** (ESI-TOF) m/z : [M]⁺ Calcd for C₁₆H₃₀O₂Si⁺, 282.2010; Found, 282.2009.

6,6-Diethoxy-1-(2-fluorophenyl)hex-2-yn-1-ol (29a)

1134 mg, 81%, yellow oil, **¹H NMR** (600 MHz, CDCl₃) δ 7.62 (dt, J = 7.6, 1.6 Hz, 1H), 7.33–7.29 (m, 1H), 7.21–7.11 (m, 1H), 7.09–7.02 (m, 1H), 5.71 (t, J = 1.9 Hz, 1H), 4.59 (t, J = 5.7 Hz, 1H), 3.71–3.58 (m, 2H), 3.56–3.44 (m, 2H), 2.34 (td, J = 7.3, 2.0 Hz, 2H), 1.86–1.81 (m, 2H), 1.29–1.15 (m, 6H). **¹³C{¹H} NMR** (101 MHz, CDCl₃) δ 160.2 (d, $J_{\text{C-F}}$ = 248.0 Hz), 130.0 (d, $J_{\text{C-F}}$ = 8.3 Hz), 128.5 (d, $J_{\text{C-F}}$ = 13.1 Hz), 128.3 (d, $J_{\text{C-F}}$ = 3.6 Hz), 124.3 (d, $J_{\text{C-F}}$ = 3.6 Hz), 115.6 (d, $J_{\text{C-F}}$ = 21.3 Hz) 101.8, 86.8, 79.3, 61.7, 59.2 (d, $J_{\text{C-F}}$ = 5.0 Hz), 32.6, 15.4, 14.5. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3402 (O-H), 2981 (C-H), 2942 (C-H), 2888 (C-H), 1491, 1337, 1057, 762. **HRMS** (ESI-TOF) m/z : [M+Na]⁺ Calcd for C₁₆H₂₁FO₃Na⁺, 303.1367; Found, 303.1369.

2-(4-Chlorophenyl)-7,7-diethoxyhept-3-yn-2-ol (30a)

1072 mg, 69%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.59–7.53 (m, 2H), 7.35–7.27 (m, 2H), 4.59 (t, J = 5.7 Hz, 1H), 3.65 (dq, J = 9.4, 7.1 Hz, 1H), 3.50 (dq, J = 9.4, 7.1 Hz, 1H), 2.34 (t, J = 7.3 Hz, 1H), 1.84 (td, J = 7.3, 5.7 Hz, 1H), 1.70 (s, 3H), 1.21 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 144.8, 133.4, 128.3, 126.6, 101.7, 85.2, 83.7, 69.6, 61.6, 33.6, 32.7, 15.4, 14.4. IR ν_{max} (solid/ cm^{-1}) 3415 (O-H), 2975 (C-H), 2930 (C-H), 2883 (C-H), 1487, 1397, 1054, 829. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{17}\text{H}_{23}\text{ClO}_3\text{Na}^+$, 333.1228; Found, 333.1224.

8,8-Diethoxy-2-methyloct-3-yn-2-ol (31a)

923 mg, 81%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.50 (t, J = 5.7 Hz, 1H), 3.64 (dq, J = 9.4, 7.1 Hz, 2H), 3.49 (dq, J = 9.4, 7.1 Hz, 2H), 2.21 (t, J = 7.0 Hz, 2H), 1.91 (br s, 1H), 1.70 (m, 2H), 1.66–1.52 (m, 2H), 1.48 (s, 6H), 1.20 (t, J = 7.1 Hz, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 102.6, 85.6, 82.2, 65.4, 61.1, 32.8, 31.9, 24.1, 18.6, 15.5. IR ν_{max} (solid/ cm^{-1}) 3433 (O-H), 2978 (C-H), 2926 (C-H), 2885 (C-H), 1465, 1134, 1056, 949, 761. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{25}\text{O}_3^+$, 251.1626; Found, 251.1623.

Preparation of *Syn* 1,3-Aminoalcohols

The corresponding propargylic alcohol (0.5 mmol, 1 equiv.) was dissolved in CHCl_3 (0.5 mL), 4 Å molecular sieves (300 mg, previously dried overnight at 120 °C) were added to the mixture. $\text{PPh}_3\text{AuNTf}_2$ (8 mg, 2 mol%) was added together with the corresponding amine (0.5 mmol, 1 equiv.) and the reaction was stirred at room temperature until completion (TLC, 18–66 h). Diethyl ether (1 mL) was added followed by NaCNBH_3 (62 mg, 1 mmol, 2 equiv.) and the reaction stirred for 2 h at 0 °C. After this time the solvent was removed in vacuo and the product was purified by column chromatography (EtOAc/Petrol) to give the corresponding aminoalcohol.

Different reducing agents were tested for the reduction step including LiAlH_4 , NaBH_4 , DIBAL, catecholborane, LiBHET_3 and NaBH_3CN . With all of them complete reduction of the imine was achieved, but the best selectivities for the *syn* amino alcohol were obtained using NaBH_3CN , which gave complete reduction without significant hydrolysis of the imine.

***syn*-5-(Phenylamino)tridecan-7-ol (1ba)**

After amine addition the reaction was stirred for 18h.

113 mg, 78%, pale yellow solid, mp 61–62 °C; $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.22–7.15 (m, 2H), 6.77 (t, J = 7.3 Hz, 1H), 6.69 (m, 2H), 3.89–3.81 (m, 1H), 3.60–3.54 (m, 1H), 1.75–1.69 (m, 1H), 1.56–1.40 (m, 5H), 1.30 (m, 12H), 0.89 (t, J = 6.8 Hz, 3H), 0.87 (t, J = 6.9, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 147.3, 129.4, 118.8, 115.2, 72.3, 54.6, 41.6, 38.3, 35.4, 32.0, 29.5, 28.0, 25.5, 22.9, 22.7, 14.2, 14.1. IR ν_{max} (solid/ cm^{-1}) 3367 (O-H), 2923 (C-H), 2853 (C-H), 1598 (C=C), 1497 (C=C), 1463 (C=C), 1317, 745, 691. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{34}\text{O}^+$, 292.2635; Found, 292.2633.

***syn*-5-((4-Fluorophenyl)amino)tridecan-7-ol (1bb)**

After amine addition the reaction was stirred for 24h.

98 mg, 64%, white solid, mp 66–67 °C $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 6.96–6.87 (m, 2H), 6.71–6.62 (m, 2H), 3.92–3.79 (m, 1H), 3.51–3.39 (m, 1H), 1.77–1.67 (m, 1H), 1.54–1.49 (m, 1H), 1.46–1.41 (m, 4H), 1.32–

1.25 (m, 12H), 0.89 (t, $J = 6.8$ Hz, 3H), 0.87 (t, $J = 6.9$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 156.7 (d, $J_{\text{C-F}} = 236.7$ Hz), 143.4, 116.5 (d, $J_{\text{C-F}} = 7.5$ Hz), 115.9 (d, $J_{\text{C-F}} = 22.3$ Hz), 72.4, 55.9, 41.4, 38.3, 35.25, 32.0, 29.5, 27.9, 25.5, 22.9, 22.7, 14.2, 14.1. IR ν_{max} (solid/ cm^{-1}) 3352 (O-H), 2924 (C-H), 2853 (C-H), 1506 (C=C), 1463 (C=C), 1219, 819. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{33}\text{FNO}^+$, 310.2541; Found, 310.2539.

syn-5-((3,5-Dimethylphenyl)amino)tridecan-7-ol (1bc)

After amine addition the reaction was stirred for 24h.

124 mg, 78%, colourless oil, ^1H NMR (700 MHz, CDCl_3) δ 6.43 (s, 1H), 6.34 (s, 2H), 3.83 (m, 1H), 3.52 (m, 1H), 2.23 (s, 6H), 1.71 (m, 1H), 1.53–1.46 (m, 1H), 1.45–1.35 (m, 4H), 1.29 (m, 12H), 0.89 (t, $J = 6.8$ Hz, 3H), 0.87 (t, $J = 6.8$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 147.3, 139.1, 121.0, 113.4, 72.5, 54.9, 41.5, 38.3, 35.4, 32.0, 29.5, 28.0, 25.6, 22.9, 22.8, 21.6, 14.2, 14.2. IR ν_{max} (solid/ cm^{-1}) 3367 (O-H), 2923 (C-H), 2853 (C-H), 1598 (C=C), 1463 (C=C), 1178. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{38}\text{NO}^+$, 320.2948; Found, 320.2945.

syn-5-((4-Methoxyphenyl)amino)tridecan-7-ol (1bd)

After amine addition the reaction was stirred for 48h.

143 mg, 89%, white solid, mp 65–67 °C. ^1H NMR (400 MHz, CDCl_3) δ 6.84–6.74 (m, 2H), 6.75–6.67 (m, 2H), 3.85 (m, 1H), 3.75 (s, 3H), 3.42 (m, 1H), 1.78–1.69 (m, 1H), 1.60–1.48 (m, 1H), 1.46–1.38 (m, 4H), 1.32–1.22 (m, 12H), 0.88 (t, $J = 6.8$ Hz, 3H), 0.85 (t, $J = 6.9$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 153.4, 140.8, 117.4, 114.9, 72.7, 56.8, 55.8, 41.1, 38.3, 35.3, 31.9, 29.5, 27.9, 25.5, 22.8, 22.7, 14.2, 14.1. IR ν_{max} (solid/ cm^{-1}) 3271 (O-H), 2920 (C-H), 2852 (C-H), 1507 (C=C), 1462 (C=C), 1230, 1040, 817. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{36}\text{NO}_2^+$, 322.2741; Found, 322.2739.

syn-5-((3,5-Dichlorophenyl)amino)tridecan-7-ol (1be)

After amine addition the reaction was stirred for 48h.

122 mg, 68%, pale brown oil, ^1H NMR (700 MHz, CDCl_3) δ 6.66 (s, 1H), 6.49 (s, 2H), 3.81 (br s, 1H), 3.74 (m, 1H), 3.53–3.45 (m, 1H), 1.65 (m, 1H), 1.59–1.51 (m, 3H), 1.50–1.42 (m, 2H), 1.33–1.25 (m, 12H), 0.89 (t, $J = 6.9$ Hz, 3H), 0.88 (t, $J = 6.9$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 149.4, 135.7, 117.4, 112.0, 71.3, 52.9, 41.9, 38.4, 35.0, 31.9, 29.4, 27.9, 25.5, 22.8, 22.7, 14.2, 14.2. IR ν_{max} (solid/ cm^{-1}) 3449 (O-H), 2924 (C-H), 2853 (C-H), 1583 (C=C), 1507 (C=C), 1451 (C=C), 1110, 725. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{32}\text{NOCl}_2^+$, 360.1855; Found, 360.1855.

syn-5-((3-(Trifluoromethyl)phenyl)amino)tridecan-7-ol (1bf)

After amine addition the reaction was stirred for 48h.

92 mg, 51%, pale yellow oil, ^1H NMR (600 MHz, CDCl_3) δ 7.27–7.22 (m, 1H), 6.95 (d, $J = 7.6$ Hz, 1H), 6.86 (s, 1H), 6.79 (m, 1H), 3.84–3.77 (m, 1H), 3.57 (m, 1H), 1.70 (m, 1H), 1.54 (m, 3H), 1.49–1.38 (m, 3H), 1.36–1.25 (m, 12H), 0.89 (t, $J = 6.8$ Hz, 3H), 0.87 (t, $J = 6.9$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 147.8, 131.8 (q, $J_{\text{C-F}} = 31.7$ Hz), 129.9, 124.4 (q, $J_{\text{C-F}} = 272.4$ Hz), 117.2, 114.5 (d, $J_{\text{C-F}} = 3.9$ Hz), 110.5 (d, $J_{\text{C-F}} = 3.9$ Hz), 71.6, 53.3, 41.8, 38.3, 35.1, 31.9, 29.4, 27.9, 25.5, 22.8, 22.7, 14.2, 14.1. IR ν_{max} (solid/ cm^{-1}) 3361 (O-H), 2925 (C-H), 2854 (C-H), 1612 (C=C), 1336 (C=C), 1120, 696. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{33}\text{F}_3\text{NO}^+$, 360.2509; Found, 360.2506.

***syn*-5-(*o*-Tolylamino)tridecan-7-ol (1bg)**

After amine addition the reaction was stirred for 66h.

81 mg, 53%, colourless oil, ¹H NMR (700 MHz, CDCl₃) δ 7.12 (t, *J* = 7.6 Hz, 1H), 7.06 (d, *J* = 7.3 Hz, 1H), 6.75 (d, *J* = 8.1 Hz, 1H), 6.70 (t, *J* = 7.4 Hz, 1H), 3.83 (m, 1H), 3.61 (m, 1H), 3.46 (br s, 1H), 2.15 (s, 3H), 1.76 (m, 1H), 1.55 (m, 1H), 1.50–1.41 (m, 4H), 1.31 (m, 12H), 0.89 (t, *J* = 6.8 Hz, 3H), 0.87 (t, *J* = 6.9, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃) δ 145.2, 130.6, 127.3, 123.5, 118.2, 112.4, 72.4, 54.1, 41.7, 38.3, 35.3, 32.0, 29.5, 28.0, 25.6, 22.9, 22.8, 17.9, 14.2, 14.2. IR $\nu_{\max}$ (solid/cm⁻¹) 3385 (O-H), 2923 (C-H), 2853 (C-H), 1603 (C=C), 1510 (C=C), 1476, 743. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₂₀H₃₆NO⁺, 306.2791; Found, 306.2789.

***syn*-5-((2-Bromophenyl)amino)tridecan-7-ol (1bh)**

After amine addition the reaction was stirred for 66h.

78 mg, 42%, colourless oil. ¹H NMR (700 MHz, CDCl₃) δ 7.42 (d, *J* = 7.9 Hz, 1H), 7.17 (t, *J* = 7.3 Hz, 1H), 6.77 (d, *J* = 8.2 Hz, 1H), 6.58 (t, *J* = 7.6 Hz, 1H), 3.79 (m, 1H), 3.64–3.58 (m, 1H), 1.74–1.69 (m, 1H), 1.62 (m, 2H), 1.51–1.39 (m, 3H), 1.29 (m, 12H), 0.93–0.84 (m, 6H). ¹³C{¹H} NMR (176 MHz, CDCl₃) δ 144.5, 132.7, 128.6, 118.5, 113.3, 111.2, 71.2, 53.4, 42.0, 38.3, 35.06, 32.0, 29.5, 27.9, 25.6, 22.9, 22.7, 14.2, 14.2. IR $\nu_{\max}$ (solid/cm⁻¹) 3402 (O-H), 2923 (C-H), 2853 (C-H), 1594 (C=C), 1507 (C=C), 1457 (C=C), 1016, 738. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₉H₃₃NOBr⁺, 370.1739; Found, 370.1739.

1-(2-(Phenylamino)hexyl)cyclohexan-1-ol (2ba)

After amine addition the reaction was stirred for 18h.

66 mg, 48%, colourless oil, ¹H NMR (600 MHz, CDCl₃) δ 7.22–7.12 (m, 2H), 6.77 (tt, *J* = 7.4, 1.0 Hz, 1H), 6.69 (m, 2H), 3.72–3.60 (m, 2H), 1.81 (dd, *J* = 14.7, 2.5 Hz, 1H), 1.71–1.21 (m, 14H), 0.88–0.83 (m, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 147.0, 129.5, 119.0, 115.4, 71.4, 50.7, 40.5, 40.0, 36.9, 35.6, 28.1, 26.1, 22.9, 22.5, 22.3, 14.2. IR $\nu_{\max}$ (solid/cm⁻¹) 3345 (O-H), 2924 (C-H), 2853 (C-H), 1598 (C=C), 1496 (C=C), 1376 (C=C), 1159, 747. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₈H₃₀NO⁺, 376.2322; Found, 276.2327.

***syn*-1-(2-Chlorophenyl)-3-(phenylamino)heptan-1-ol (3ba)**

After amine addition the reaction was stirred for 18h.

105 mg, 48%, colourless oil, ¹H NMR (700 MHz, CDCl₃) δ 7.64 (d, *J* = 7.6 Hz, 1H), 7.33 (d, *J* = 7.9 Hz, 1H), 7.30 (d, *J* = 7.5 Hz, 1H), 7.22 (t, *J* = 7.6 Hz, 2H), 7.21–7.18 (m, 1H), 6.82 (t, *J* = 7.2 Hz, 1H), 6.78 (d, *J* = 7.9 Hz, 2H), 5.33 (m, 1H), 3.74 (m, 1H), 2.09 (m, 1H), 1.65–1.53 (m, 3H), 1.53–1.47 (m, 1H), 1.35–1.24 (m, 3H), 0.86 (t, *J* = 6.7 Hz, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃) δ 147.1, 142.2, 131.5, 129.5, 129.4, 128.4, 127.3, 127.1, 119.4, 115.7, 71.5, 55.2, 42.1, 35.2, 27.9, 22.8, 14.2. IR $\nu_{\max}$ (solid/cm⁻¹) 3379 (O-H), 2925 (C-H), 2854 (C-H), 1598 (C=C), 1496 (C=C), 990, 749. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₉H₂₄NOCl⁺, 318.1619; Found, 318.1614.

(2*R*S,4*R*S)-2-(4-Chlorophenyl)-4-(phenylamino)octan-2-ol (4ba)

After amine addition the reaction was stirred for 18h.

129 mg, 78%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.43 (d, J = 7.7 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H), 7.22 (t, J = 7.3 Hz, 2H), 6.83 (t, J = 7.2 Hz, 1H), 6.73 (d, J = 7.8 Hz, 2H), 3.78 (m, 1H), 1.99 (d, J = 14.7 Hz, 1H), 1.74 (dd, J = 14.5, 11.1 Hz, 1H), 1.64 (s, 3H), 1.59–1.49 (m, 1H), 1.39 (dd, J = 14.2, 6.9 Hz, 1H), 1.31–1.19 (m, 4H), 0.84 (t, J = 6.0 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 148.3, 146.6, 132.4, 129.6, 128.4, 126.2, 119.8, 115.8, 74.0, 52.3, 47.4, 35.6, 29.1, 28.0, 22.8, 14.1. IR ν_{max} (solid/ cm^{-1}) 3320 (O-H), 2926 (C-H), 2854 (C-H), 1598 (C=C), 1496 (C=C), 1091, 750. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{27}\text{ClNO}^+$, 332.1776; Found, 332.1773.

***syn*-1-Phenyl-1-(phenylamino)nonan-3-ol (5ba)**

After amine addition the reaction was stirred for 18h.

79 mg, 51%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.37 (m, 5H), 7.22–7.14 (m, 2H), 6.73 (t, J = 7.2 Hz, 1H), 6.65 (m, 2H), 5.06–4.96 (dd, J = 8.2, 2.8 Hz, 1H), 3.60 (m, 1H), 2.12–2.03 (m, 1H), 1.85–1.78 (m, 1H), 1.37–1.16 (m, 10H), 0.86 (t, J = 6.8 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 145.1, 129.5, 128.6, 127.5, 125.7, 118.2, 115.9, 114.3, 71.9, 51.3, 43.7, 35.5, 31.9, 29.4, 26.0, 22.7, 14.2. IR ν_{max} (solid/ cm^{-1}) 3377 (O-H), 2951 (C-H), 2853 (C-H), 1588 (C=C), 1506 (C=C), 1452 (C=C), 1315, 749. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{30}\text{NO}^+$, 312.2322; Found, 312.2326.

7,7-Diethoxy-2-methyl-4-(phenylamino)heptan-2-ol (6ba)

After amine addition the reaction was stirred for 18h.

112 mg, 73%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.18 (t, J = 7.9 Hz, 2H), 6.77 (t, J = 7.3 Hz, 1H), 6.71 (d, J = 7.9 Hz, 2H), 4.41 (t, J = 5.4 Hz, 1H), 3.77–3.73 (m, 1H), 3.68 (br s, 1H), 3.59 (m, 2H), 3.46–3.39 (m, 2H), 1.72 (dd, J = 14.6, 2.7 Hz, 1H), 1.68–1.58 (m, 4H), 1.50–1.46 (m, 1H), 1.29 (s, 3H), 1.24 (s, 3H), 1.19–1.13 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 146.9, 129.5, 119.1, 115.3, 102.9, 70.9, 61.4, 61.1, 51.4, 46.3, 31.5, 30.8, 29.9, 28.8, 15.4, 15.4. IR ν_{max} (solid/ cm^{-1}) 3364 (O-H), 2968 (C-H), 2927 (C-H), 1599 (C=C), 1497 (C=C), 1153, 1055. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{18}\text{H}_{32}\text{NO}_3^+$, 310.2377; Found, 310.2374.

3-Phenyl-3-(phenylamino)propan-1-ol (7ba)⁵²

After amine addition the reaction was stirred for 18h.

84 mg, 74%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.38–7.34 (m, 2H), 7.32 (m, 2H), 7.25–7.22 (m, 1H), 7.09 (m, 2H), 6.66 (t, J = 7.3 Hz, 1H), 6.56 (t, J = 8.6 Hz, 2H), 4.58 (t, J = 6.7 Hz, 1H), 3.79 (m, 2H), 2.13–2.01 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 147.4, 143.7, 129.3, 128.8, 127.21, 126.4, 117.7, 113.9, 60.9, 57.0, 40.8. IR ν_{max} (solid/ cm^{-1}) 3393 (O-H), 2938 (C-H), 1599 (C=C), 1501 (C=C), 1315.

***syn*-1,1-Diethoxy-5-phenyl-5-(phenylamino)pentan-3-ol (8ba)**

After amine addition the reaction was stirred for 18h.

138 mg, 81%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.42–7.36 (m, 2H), 7.33 (m, 2H), 7.22 (m, 1H), 7.10–7.02 (m, 2H), 6.66–6.61 (m, 1H), 6.60–6.52 (m, 2H), 4.76–4.61 (m, 1H), 4.59–4.44 (m, 1H), 4.04–3.95 (m, 1H), 3.79–3.68 (m, 1H), 3.68–3.59 (m, 1H), 3.58–3.45 (m, 2H), 2.04–1.97 (m, 1H), 1.84–1.71 (m, 3H), 1.26–1.19 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 147.6, 144.3, 129.1, 128.8, 127.2, 126.5, 117.7,

114.2, 102.4, 68.1, 62.6, 61.9, 58.4, 46.1, 41.0, 15.5, 15.4. **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{21}H_{30}NO_3^+$, 344.2220; Found, 344.2225.

***syn*-1-((4-methoxyphenyl)amino)-4-methyl-1-phenylpentan-3-ol (9bd)**

After amine addition the reaction was stirred for 48h.

The compound was isolated as a mixture of *syn*/*anti* isomers (85:15). The *syn* isomer was purified by recrystallisation from *n*-hexane. 97 mg, 67%, colourless crystals, mp 99–101 °C. **1H NMR** (700 MHz, $CDCl_3$) δ 7.31 (m, 4H), 7.22 (m, 1H), 6.68 (d, J = 8.9 Hz, 2H), 6.55 (d, J = 8.9 Hz, 2H), 4.46–4.40 (m, 1H), 3.69 (s, 3H), 3.64 (m, 1H), 1.84 (m, 2H), 1.71–1.64 (m, 1H), 1.57 (br s, 1H), 0.91 (m, 6H). **$^{13}C\{^1H\}$ NMR** (176 MHz, $CDCl_3$) δ 152.9, 144.2, 141.1, 128.8, 127.2, 126.3, 116.5, 114.8, 76.9, 60.5, 55.8, 42.1, 34.47, 18.5, 17.4. **IR** ν_{max} (solid/ cm^{-1}) 3375 (O-H), 2955 (C-H), 1603 (C=C), 1513 (C=C), 1325.

This compound was synthesized from the corresponding racemic propargylic alcohol and from an enantiomerically enriched sample. From the enantiomerically enriched propargylic alcohol, the yield after crystallization was 59% (84 mg), $[\alpha]_D^{25}$ = +14.2 (c = 1.0, CH_2Cl_2). Only one enantiomer was observed by chiral HPLC.

***cis*-4-Butyl-6-hexyl-3-phenyl-1,3-oxazinan-2-one (1ba-URE)**

Compound **1ba** (29 mg, 0.1 mmol, 1 equiv.) was mixed with carbonyldiimidazole (16 mg, 0.1 mmol, 1 equiv.) and dissolved in MeCN (0.5 mL). The mixture was heated to 80 °C. After 14 h the mixture was cooled down to rt and the product was purified by flash column chromatography (AcOEt: Hex). The nOeSY spectrum of the product supports the stereochemical assignment shown above. nOeSY spectrum is included in the supporting information.

28 mg, 85%, pale yellow oil, **1H NMR** (400 MHz, $CDCl_3$) δ 7.39 (dd, J = 10.7, 4.5 Hz, 2H), 7.31–7.27 (m, 1H), 7.24 (t, J = 3.1 Hz, 2H), 4.40–4.26 (m, 1H), 3.88–3.79 (m, 1H), 2.18 (m, 1H), 1.81–1.62 (m, 3H), 1.54–1.03 (m, 14H), 0.89 (t, J = 7.0 Hz, 3H), 0.79 (t, J = 7.1, 3H). **$^{13}C\{^1H\}$ NMR** (176 MHz, $CDCl_3$) δ 154.0, 140.2, 129.2, 128.4, 127.4, 76.0, 57.6, 35.2, 34.3, 33.8, 31.8, 29.3, 26.9, 24.8, 22.7, 22.6, 14.2, 14.0. **IR** ν_{max} (solid/ cm^{-1}) 2955 (C-H), 2928 (C-H), 2858 (C-H), 1693 (C=O), 1415, 1297, 766, 696. **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{20}H_{32}NO_2^+$, 318.2428; Found, 318.2426.

(4*RS*,6*RS*)-4-Butyl-6-(4-chlorophenyl)-6-methyl-3-phenyl-1,3-oxazinan-2-one (4ba-URE)

Compound **4ba** (33 mg, 0.1 mmol, 1 equiv.) was mixed with CDI (16 mg, 0.1 mmol, 1 equiv.) and dissolved in MeCN (0.5 mL). The mixture was heated to 80 °C. After 14 h the mixture was cooled down to rt and the product was purified by flash column chromatography (AcOEt: Hex). The nOeSY spectrum of the product supports the stereochemical assignment shown above. nOeSY spectrum is included in the supporting information.

33 mg, 92%, colourless oil, **1H NMR** (400 MHz, $CDCl_3$) δ 7.46–7.39 (m, 2H), 7.34–7.28 (m, 2H), 7.21 (dd, J = 8.5, 7.4 Hz, 2H), 6.83 (t, J = 7.4 Hz, 1H), 6.72 (dd, J = 8.6, 1.0 Hz, 2H), 3.78 (td, J = 6.7, 3.3 Hz, 1H), 1.99 (dd, J = 14.7, 2.7 Hz, 1H), 1.78–1.68 (m, 1H), 1.63 (s, 3H), 1.41 (d, J = 6.8 Hz, 2H), 1.30–1.19 (m, 4H), 0.84 (m, 3H). **$^{13}C\{^1H\}$ NMR** (176 MHz, $CDCl_3$) δ 150.4, 146.6, 139.4, 132.9, 129.4, 129.2, 128.8, 128.6, 126.3, 73.9, 58.5, 46.8, 34.4, 30.4, 29.0, 22.6, 14.1. **IR** ν_{max} (solid/ cm^{-1}) 2964 (C-H), 2929 (C-H), 2859 (C-H) 1685 (C=O), 1596 (C=C), 1495 (C=C), 1215, 754, 696. **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{21}H_{25}NO_2Cl^+$, 358.1568; Found, 358.1568.

syn-5-Aminotridecan-7-ol (1bi)

To a solution of aminoalcohol **1bd** (118 mg, 0.5 mmol) in MeCN/H₂O (10 mL, 1:1) trichloroisocyanuric acid (0.13 g, 0.27 mmol) and 1 M aqueous H₂SO₄ (0.5 mL) were added. The mixture was stirred for 16 h. at rt and then the product was extracted with CH₂Cl₂ (3 x 50 mL) and the combined organic extracts concentrated. The amino alcohol was purified using flash column chromatography.

78 mg, 72%, brown oil, ¹H NMR (400 MHz, CDCl₃) δ 3.81 (m, 1H), 3.29 (m, 1H), 1.79 (m, 1H), 1.67 (m, 2H), 1.54 (m, 1H), 1.42 (m, 2H), 1.38–1.22 (m, 12H), 0.89 (t, *J* = 6.8, 1.9 Hz, 3H), 0.87 (t, *J* = 6.9, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 72.6, 53.2, 38.8, 38.6, 34.7, 31.9, 29.4, 27.8, 25.7, 22.7, 22.5, 14.1, 14.0. IR $\nu_{\max}$ (solid/cm⁻¹) 3371 (O-H), 3195 (N-H) 2955 (C-H), 2912 (C-H), 1154, 1092, 752, 692. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₃H₃₀NO⁺, 216.2322; Found, 216.2323.

Preparation of Hydroxyketones

The corresponding propargylic alcohol (0.5 mmol, 1 equiv.) was dissolved in undried CHCl₃ (0.5 mL). After the substrate was completely dissolved, PPh₃AuNTf₂ (8 mg, 2 mol%) and 3-trifluoromethylaniline (16 mg, 0.2 equiv.) were added to the solution. The reaction was then stirred at 50 °C for 18 h. The solvent was removed in vacuo and the product was purified by column chromatography (AcOEt:Hex, 1:4).

7-Hydroxytridecan-5-one (1c)

96 mg, 91%, pale yellow solid, mp 47-49 °C; ¹H NMR (600 MHz, CDCl₃) δ 4.08–3.93 (m, 1H), 3.04 (d, *J* = 3.0 Hz, 1H), 2.58 (dd, *J* = 17.5, 2.7 Hz, 1H), 2.48 (dd, *J* = 17.5, 9.2 Hz, 1H), 2.42 (t, *J* = 7.6 Hz, 2H), 1.59–1.52 (m, 2H), 1.51–1.45 (m, 1H), 1.42–1.35 (m, 2H), 1.33–1.22 (m, 9H), 0.90 (t, 7.3 Hz, 3H), 0.87 (t, 7.2 Hz, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 212.8, 67.8, 49.0, 43.5, 36.6, 31.9, 29.3, 25.8, 25.5, 22.7, 22.4, 14.2, 13.9. IR $\nu_{\max}$ (solid/cm⁻¹) 3397 (O-H), 2956 (C-H), 2928 (C-H), 2857 (C-H), 1705 (C=O), 1465, 1378, 1164, 732. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₃H₂₇O₂⁺, 215.2006; Found, 215.2006.

1-(1-Hydroxycyclohexyl)hexan-2-one (2c)

80 mg, 81%, yellow oil, ¹H NMR (600 MHz, CDCl₃) δ 3.77 (br s, 1H), 2.56 (s, 2H), 2.41 (t, *J* = 7.4 Hz, 2H), 1.72–1.61 (m, 5H), 1.59–1.52 (m, 3H), 1.45–1.23 (m, 6H), 0.91 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 213.8, 70.8, 44.7, 37.7, 37.7, 25.9, 25.7, 22.4, 22.1, 14.0. IR $\nu_{\max}$ (solid/cm⁻¹) 3497 (O-H), 2931 (C-H), 2859 (C-H), 1698 (C=O), 1447, 1406, 996. HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₂H₂₃O₂⁺, 199.1693; Found, 199.1692.

1-(2-Chlorophenyl)-1-hydroxyheptan-3-one (3c)

103 mg, 86%, yellow oil, ¹H NMR (600 MHz, CDCl₃) δ 7.62 (dd, *J* = 7.8, 1.6 Hz, 1H), 7.34–7.28 (m, 2H), 7.23–7.18 (m, 1H), 5.49 (dt, *J* = 9.6, 2.7 Hz, 1H), 3.66 (d, *J* = 3.3 Hz, 1H), 2.97 (dd, *J* = 17.6, 2.3 Hz, 1H), 2.63 (dd, *J* = 17.6, 9.6 Hz, 1H), 2.44 (m, 2H), 1.58 (m, 2H), 0.90 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 212.1, 140.3, 131.2, 129.4, 128.7, 127.3, 127.2, 66.9, 49.0, 43.4, 25.8, 22.4, 13.9. IR $\nu_{\max}$

(solid/cm⁻¹) 3449 (O-H), 2958 (C-H), 2931 (C-H), 2872 (C-H), 1703 (C=O), 1439, 1047, 1032, 753. **HRMS** (ESI-TOF) *m/z*: [M]⁺ Calcd for C₁₃H₁₇ClO₂⁺, 240.0912; Found, 240.0911.

2-(4-Chlorophenyl)-2-hydroxyoctan-4-one (4c)

55 mg, 43%, yellow oil, ¹H NMR (600 MHz, CDCl₃) δ 7.39–7.33 (m, 2H), 7.30–7.27 (m, 2H), 4.71 (s, 1H), 3.10 (d, *J* = 17.1 Hz, 1H), 2.80 (d, *J* = 17.1 Hz, 1H), 2.36 (m, 1H), 2.26 (m, 1H), 1.48 (s, 3H), 1.47–1.40 (m, 2H), 1.20 (m, 2H), 0.84 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 213.1, 146.1, 132.7, 128.5, 126.0, 73.2, 53.0, 44.5, 30.7, 25.4, 22.2, 13.8. IR *v*_{max} (solid/cm⁻¹) 3470 (O-H), 2958 (C-H), 2931 (C-H), 2872 (C-H), 1696 (C=O), 1489, 1401, 1164, 1094, 1012, 829, 555. **HRMS** (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₉ClO₂Na⁺, 277.0967; Found, 277.0967.

3-Hydroxy-1-phenylnonan-1-one (5c)⁵³

95 mg, 81%, yellow oil, ¹H NMR (400 MHz, CDCl₃) δ 8.00–7.91 (m, 2H), 7.63–7.55 (m, 1H), 7.50–7.44 (m, 2H), 4.22 (m, 1H), 3.17 (dd, *J* = 17.7, 2.6 Hz, 1H), 3.04 (dd, *J* = 17.7, 9.0 Hz, 1H), 1.68–1.57 (m, 1H), 1.50 (m, 2H), 1.35–1.24 (m, 7H), 0.89 (t, *J* = 7.1 Hz, 3H). ¹³C{¹H} NMR (101 MHz, CDCl₃) δ 201.1, 136.9, 133.6, 128.7, 128.1, 67.9, 45.1, 36.6, 31.9, 29.3, 25.6, 22.7, 14.2. IR *v*_{max} (solid/cm⁻¹) 3452 (O-H), 2957 (C-H), 2931 (C-H), 2872 (C-H), 1703 (C=O), 1493, 1379, 1068, 698.

1,1-Diethoxy-6-hydroxy-6-methylheptan-4-one (6c)

60 mg, 78%, yellow oil, ¹H NMR (600 MHz, CDCl₃) δ 4.48 (t, *J* = 5.3 Hz, 1H), 3.83 (s, 1H), 3.63 (dq, *J* = 9.4, 7.1 Hz, 2H), 3.55–3.40 (m, 2H), 2.61 (s, 2H), 2.51 (t, *J* = 7.2 Hz, 2H), 1.89 (td, *J* = 7.2, 5.4 Hz, 2H), 1.23 (s, 6H), 1.18 (t, *J* = 7.1 Hz, 6H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 212.6, 102.0, 69.8, 61.9, 53.2, 39.3, 29.5, 27.5, 15.4. IR *v*_{max} (solid/cm⁻¹) 3475 (O-H), 2973 (C-H), 2931 (C-H), 2896 (C-H), 1700 (C=O), 1444, 1373, 1123, 1055. **HRMS** (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₁₂H₂₄O₄Na⁺, 255.1567; Found, 255.1567.

3-Hydroxy-1-phenylpropan-1-one (7c)⁵⁴

56 mg, 74%, yellow oil, ¹H NMR (600 MHz, CDCl₃) δ 8.03–7.93 (m, 2H), 7.63–7.56 (m, 1H), 7.50–7.46 (m, 2H), 4.03 (m, 2H), 3.28–3.20 (m, 2H), 2.65 (t, *J* = 6.5 Hz, 1H); ¹³C{¹H} NMR (151 MHz, CDCl₃) δ 200.7, 136.8, 133.7, 128.8, 128.2, 58.2, 40.5. IR *v*_{max} (solid/cm⁻¹) 3403 (O-H), 2925 (C-H), 1677 (C=O), 1492, 1327, 1177, 1057, 688.

3-Hydroxy-4-methyl-1-phenylpentan-1-one (9c)²³

72 mg, 82%, colourless oil, ¹H NMR (600 MHz, CDCl₃) δ 7.96 (dt, *J* = 8.5, 1.5 Hz, 2H), 7.62–7.56 (m, 1H), 7.52–7.44 (m, 2H), 4.04–3.97 (m, 1H), 3.21–3.12 (m, 2H), 3.03 (dd, *J* = 17.4, 9.6 Hz, 1H), 1.86–1.76 (m, 1H), 1.01 (d, *J* = 6.8 Hz, 3H), 0.99 (d, *J* = 6.8 Hz, 3H). ¹³C{¹H} NMR (176 MHz, CDCl₃) δ 201.5, 137.1, 133.6, 128.8, 128.2, 72.5, 42.1, 33.3, 18.7, 18.0. IR *v*_{max} (solid/cm⁻¹) 3488 (O-H), 2961 (C-H), 2911 (C-H), 2867 (C-H), 1704 (C=O), 1467, 1355, 1235, 995, 737.

This compound was synthesized from the corresponding racemic propargylic alcohol and from an enantiomerically enriched sample. From the enantiomerically enriched propargylic alcohol, the yield

was 86%, $[\alpha]_D^{25} = +6.3$ ($c = 1.0$, CH_2Cl_2). An e.r. of 94:6 was observed by chiral HPLC (supporting information).

1-Hydroxy-1-(4-methoxyphenyl)heptan-3-one (10c)⁵⁵

61 mg, 52%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.27 (m, 2H), 6.99–6.77 (m, 2H), 5.09 (dd, $J = 9.2$, 3.0 Hz, 1H), 3.79 (s, 3H), 3.29 (br s, 1H), 2.84 (dd, $J = 17.3$, 9.3 Hz, 1H), 2.75 (dd, $J = 17.3$, 3.2 Hz, 1H), 2.42 (t, $J = 7.6$ Hz, 2H), 1.57–1.51 (m, 2H), 1.40–1.24 (m, 2H), 0.89 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 211.8, 159.2, 135.2, 127.0, 114.0, 69.8, 55.4, 51.1, 43.6, 25.8, 22.4, 13.9. IR ν_{max} (solid/ cm^{-1}) 3433 (O-H), 2957 (C-H), 2931 (C-H), 2872 (C-H), 1704 (C=O), 1611, 1512, 1245, 1033, 830.

1-(Furan-2-yl)-1-hydroxyheptan-3-one (11c)⁵⁶

75 mg, 77%, yellow oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.36 (dd, $J = 1.8$, 0.8 Hz, 1H), 6.32 (dd, $J = 3.2$, 1.8 Hz, 1H), 6.25 (d, $J = 3.2$ Hz, 1H), 5.16 (m, 1H), 3.31 (br s, 1H), 3.02 (dd, $J = 17.5$, 8.9 Hz, 1H), 2.89 (dd, $J = 17.5$, 3.3 Hz, 1H), 2.45 (t, $J = 7.4$ Hz, 2H), 1.63–1.53 (m, 2H), 1.38–1.26 (m, 2H), 0.90 (t, $J = 7.4$ Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 211.2, 155.2, 142.2, 110.4, 106.4, 64.0, 47.2, 43.5, 25.8, 22.4, 13.9. IR ν_{max} (solid/ cm^{-1}) 3451 (O-H), 2958 (C-H), 2933 (C-H), 2873 (C-H), 1709 (C=O), 1378, 1012, 739.

1-Hydroxy-1-(thiophen-2-yl)heptan-3-one (12c)⁵⁷

60 mg, 61%, brown oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.25–7.22 (m, 1H), 6.97–6.94 (m, 2H), 5.40 (dt, $J = 8.6$, 3.5 Hz, 1H), 3.51 (d, $J = 3.7$ Hz, 1H), 2.98 (dd, $J = 17.6$, 3.6 Hz, 1H), 2.92 (dd, $J = 17.6$, 8.6 Hz, 1H), 2.45 (t, $J = 7.4$ Hz, 2H), 1.65–1.52 (m, 2H), 1.35–1.28 (m, 2H), 0.90 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 211.3, 146.7, 126.8, 124.8, 123.6, 66.4, 50.9, 43.5, 25.7, 22.4, 13.9. IR ν_{max} (solid/ cm^{-1}) 3433 (O-H), 2957 (C-H), 2931 (C-H), 2872 (C-H), 1706 (C=O), 1404, 1126, 1036, 699.

3-Hydroxy-2-methylnonan-5-one (13c)⁵⁸

79 mg, 92%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.84–3.77 (m, 1H), 2.63–2.55 (dd, $J = 17.6$, 2.3 Hz, 1H), 2.48 (dd, $J = 17.6$, 9.6 Hz, 1H), 2.44 (t, $J = 7.4$ Hz, 2H), 1.67 (m, 1H), 1.61–1.51 (m, 2H), 1.37–1.26 (m, 2H), 0.95–0.88 (m, 9H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 212.9, 72.4, 46.0, 43.5, 33.1, 25.8, 22.3, 18.4, 17.8, 13.9. IR ν_{max} (solid/ cm^{-1}) 3397 (O-H), 2959 (C-H), 2932 (C-H), 2873 (C-H), 1702 (C=O), 1333, 1164, 1125, 1070 698.

1-Cyclohexyl-1-hydroxyheptan-3-one (14c)⁵⁵

99 mg, 94%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 3.79 (m, 1H), 2.96 (d, $J = 3.5$ Hz, 1H), 2.59 (dd, $J = 17.3$, 2.4 Hz, 1H), 2.50 (dd, $J = 17.3$, 9.6 Hz, 1H), 2.43 (t, $J = 7.5$ Hz, 2H), 1.87–1.80 (m, 1H), 1.74 (m, 2H), 1.68–1.60 (m, 2H), 1.60–1.51 (m, 2H), 1.38–1.27 (m, 3H), 1.26–1.09 (m, 3H), 1.07–0.96 (m, 2H), 0.90 (t, $J = 7.4$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 213.1, 71.9, 46.2, 43.6, 43.1, 29.0, 28.4, 26.6, 26.2, 25.9, 22.4, 14.0. IR ν_{max} (solid/ cm^{-1}) 3458 (O-H), 2991 (C-H), 2933 (C-H), 2859 (C-H), 1703 (C=O), 1417, 1106, 796.

7,16-Dihydroxydocosane-9,14-dione (15c)

149 mg, 81%, yellow oil, mixture of diastereoisomers (overlapped cannot differentiate most peaks) **¹H NMR** (600 MHz, CDCl₃) δ 4.06–3.99 (m, 2H), 2.63–2.54 (m, 2H), 2.54–2.48 (m, 2H), 2.42 (m, 4H), 2.13 (s, 2H), 1.61–1.55 (m, 4H), 1.52–1.47 (m, 2H), 1.44–1.37 (m, 4H), 1.34–1.23 (m, 14H), 0.88 (t, *J* = 6.7 Hz, 6H). **¹³C{¹H} NMR** (151 MHz, CDCl₃) δ 212.0 (*diastereomer 1*), 208.8 (*diastereomer 1*), 67.8, 49.2, 43.5, 36.6, 31.9, 29.3, 25.5, 22.7, 14.2. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3326 (O-H), 2926 (C-H), 2856 (C-H), 1702 (C=O), 1332, 1166, 1127, 667. **HRMS** (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₂₂H₄₂O₄Na⁺, 393.2975; Found, 393.2983.

1-Hydroxy-1-(4-nitrophenyl)-5-phenylpentan-3-one (16c)

113 mg, 76%, yellow oil, **¹H NMR** (400 MHz, CDCl₃) δ 8.28–8.18 (m, 2H), 7.56–7.45 (m, 2H), 7.29 (m, 2H), 7.24–7.19 (m, 1H), 7.18–7.15 (m, 2H), 5.24 (m, 1H), 3.56 (d, *J* = 3.3 Hz, 1H), 2.93 (m, 2H), 2.79 (m, 4H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) δ 209.9, 150.0, 147.4, 140.4, 128.7, 128.35, 127.1, 126.5, 123.8, 69.1, 51.0, 45.1, 29.6. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3464 (O-H), 2927 (C-H), 1706 (C=O), 1601, 1515, 1342, 854, 697. **HRMS** (ESI-TOF) *m/z*: [M+Cl]⁺ Calcd for C₁₇H₁₇ClNO₄⁺, 334.0846; Found, 334.0851.

3-(4-Bromophenyl)-1-cyclopropyl-3-hydroxypropan-1-one (17c)

79 mg, 59%, pale yellow solid, mp 93–94 °C **¹H NMR** (400 MHz, CDCl₃) δ 7.52–7.44 (m, 2H), 7.29–7.20 (m, 2H), 5.12 (m, 1H), 3.58 (d, *J* = 3.0 Hz, 1H), 2.98–2.93 (m, 2H), 1.91 (tt, *J* = 7.8, 4.5 Hz, 1H), 1.16–1.06 (m, 2H), 1.01–0.90 (m, 2H); **¹³C{¹H} NMR** (101 MHz, CDCl₃) δ 211.2, 141.9, 131.7, 127.5, 121.4, 69.4, 51.4, 21.4, 11.6, 11.4. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3433 (O-H), 2920 (C-H), 2900 (C-H), 1686 (C=O), 1420, 1055, 1027, 819, 532. **HRMS** (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₃O₂BrNa⁺, 290.9991; Found, 291.0001.

3-Ethyl-3-hydroxynonan-5-one (18c)

30 mg, 32%, yellow oil, **¹H NMR** (600 MHz, CDCl₃) δ 3.81 (s, 1H), 2.55 (s, 2H), 2.43 (t, *J* = 7.4 Hz, 2H), 1.61–1.47 (m, 6H), 1.35–1.31 (m, 2H), 0.91 (t, *J* = 7.3 Hz, 3H), 0.85 (t, *J* = 7.5 Hz, 6H). **¹³C{¹H} NMR** (151 MHz, CDCl₃) δ 214.2, 74.3, 48.7, 44.7, 31.2, 25.7, 22.4, 14.0, 8.2. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3463 (O-H), 2960 (C-H), 2930 (C-H), 2874 (C-H), 1698 (C=O), 1488, 1459, 1407, 1126, 1061, 976. **HRMS** (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₁₁H₂₂O₂Na⁺, 209.1517; Found, 209.1514.

1-Hydroxy-1-phenylheptan-3-one (19c)⁵⁵

84 mg, 82%, colourless oil, **¹H NMR** (400 MHz, CDCl₃) δ 7.42–7.32 (m, 4H), 7.28 (m, 1H) 5.16 (m, 1H), 3.37 (d, *J* = 3.1 Hz, 1H), 2.92–2.71 (m, 2H), 2.43 (t, *J* = 7.4 Hz, 2H), 1.64–1.51 (m, 2H), 1.40–1.23 (m, 2H), 0.90 (t, *J* = 7.2 Hz, 3H). **¹³C{¹H} NMR** (101 MHz, CDCl₃) δ 211.8, 142.9, 128.6, 127.7, 125.7, 70.0, 51.1, 43.5, 25.7, 22.3, 13.9. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3485 (O-H), 2959 (C-H), 2932 (C-H), 2873 (C-H), 1703 (C=O), 1494, 1128, 905, 725, 699.

1-Hydroxyhexan-3-one (20c)⁵⁸

43 mg, 74%, yellow oil, ^1H NMR (600 MHz, CDCl_3) δ 3.84 (t, J = 5.4 Hz, 2H), 2.72–2.62 (m, 2H), 2.53–2.36 (m, 2H), 1.71–1.55 (m, 2H), 0.91 (t, J = 7.4 Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 212.1, 58.0, 45.4, 44.4, 17.2, 13.8. IR ν_{max} (solid/ cm^{-1}) 3397 (O-H), 2963 (C-H), 2932 (C-H), 1704 (C=O), 1349, 1226, 1189, 729.

1-Cyclopropyl-3-hydroxy-3-*p*-tolylpropan-1-one (21c)

72 mg, 71%, yellow oil, ^1H NMR (600 MHz, CDCl_3) δ 7.28–7.24 (m, 2H), 7.16 (d, J = 7.9 Hz, 2H), 5.12 (dd, J = 8.7, 3.5 Hz, 1H), 3.52–3.37 (m, 1H), 3.04–2.90 (m, 1H), 2.34 (s, 1H), 1.92 (m, 1H), 1.14–1.04 (m, 2H), 0.94–0.89 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 211.5, 140.0, 137.4, 129.3, 125.7, 69.9, 51.7, 21.5, 21.2, 11.5, 11.2. IR ν_{max} (solid/ cm^{-1}) 3430 (O-H), 3009 (C-H), 2923 (C-H), 1686 (C=O), 1514, 1387, 1103, 1056, 815. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{13}\text{H}_{16}\text{O}_2\text{Na}^+$, 227.1043; Found, 227.1049.

3-Ethyl-3-hydroxy-1-*p*-tolylpentan-1-one (22c)

83 mg, 75%, yellow oil, ^1H NMR (600 MHz, CDCl_3) δ 7.90–7.81 (m, 2H), 7.30–7.24 (m, 2H), 4.14 (s, 1H), 3.06 (s, 2H), 2.41 (s, 3H), 1.65–1.54 (m, 4H), 0.90 (t, J = 7.5 Hz, 6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 202.3, 144.7, 135.2, 129.5, 128.3, 74.6, 44.0, 31.4, 21.8, 8.3. IR ν_{max} (solid/ cm^{-1}) 3473 (O-H), 2966 (C-H), 2936 (C-H), 2880 (C-H), 1663 (C=O), 1605, 1407, 1122, 781. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{21}\text{O}_2^+$, 221.1542; Found, 221.1540.

1-Cyclohexyl-6,6-diethoxy-1-hydroxyhexan-3-one (23c)

110 mg, 77%, yellow oil, ^1H NMR (600 MHz, CDCl_3) δ 4.48 (t, J = 5.3 Hz, 1H), 3.80 (m, 1H), 3.63 (m, 2H), 3.53–3.43 (m, 2H), 2.93 (d, J = 3.6 Hz, 1H), 2.64–2.58 (dd, J = 17.1, 2.6 Hz, 1H), 2.53 (m, 3H), 1.91 (td, J = 7.2, 5.3 Hz, 2H), 1.84 (m, 1H), 1.79–1.71 (m, 2H), 1.69–1.61 (m, 2H), 1.39–1.31 (m, 1H), 1.27–1.21 (m, 2H), 1.19 (t, J = 6.9 Hz, 3H), 1.18 (t, J = 6.9 Hz, 3H), 1.15 (m, 1H), 1.02 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 212.2, 102.1, 71.9, 61.9, 61.8, 46.5, 43.2, 38.5, 29.0, 28.4, 27.7, 26.6, 26.3, 26.2, 15.4. IR ν_{max} (solid/ cm^{-1}) 3463 (O-H), 2971 (C-H), 2926 (C-H), 2853 (C-H), 1706 (C=O), 1484, 1407, 1123, 1058. HRMS Found 309.2038, $[\text{C}_{16}\text{H}_{30}\text{O}_4+\text{Na}]^+$ requires 309.2036. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{16}\text{H}_{30}\text{O}_4\text{Na}^+$, 309.2036; Found, 309.2038.

4-(1-Hydroxy-3-oxoheptyl)benzonitrile (24c)

103 mg, 89%, colourless oil, ^1H NMR (600 MHz, CDCl_3) δ 7.65 (m, 2H), 7.48 (m, 2H), 5.26–5.12 (m, 1H), 3.79–3.56 (br s, 1H), 2.93–2.71 (m, 2H), 2.58–2.37 (m, 2H), 1.60–1.50 (m, 2H), 1.35–1.26 (m, 2H), 0.89 (t, J = 7.6 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 211.3, 148.3, 132.5, 126.5, 118.9, 111.5, 69.3, 50.7, 43.5, 25.7, 22.3, 13.9. IR ν_{max} (solid/ cm^{-1}) 3472 (O-H), 2958 (C-H), 2932 (C-H), 2872 (C-H), 2228 (CN), 1705 (C=O), 1608, 1328, 1124, 832, 566. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{14}\text{H}_{17}\text{O}_2\text{Na}^+$, 254.1158; Found, 254.1148.

1,1-Diethoxy-6-hydroxydodecan-4-one (25c)

106 mg, 74%, yellow oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.47 (t, $J = 5.3$ Hz, 1H), 4.01 (m, 1H), 3.62 (m, 2H), 3.46 (m, 2H), 2.60 (dd, $J = 17.2, 2.8$ Hz, 1H), 2.55–2.43 (m, 3H), 1.90 (m, 2H), 1.54–1.22 (m, 8H), 1.18 (m, 6H), 0.89–0.84 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 211.9, 102.0, 67.9, 61.9, 61.8, 49.3, 38.4, 36.6, 31.9, 29.3, 27.7, 25.5, 22.7, 15.4, 14.2. IR ν_{max} (solid/ cm^{-1}) 3453 (O-H), 2956 (C-H), 2927 (C-H), 2857 (C-H), 1708 (C=O), 1409, 1373, 1122, 1057. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{16}\text{H}_{32}\text{O}_4\text{Na}^+$, 311.2193; Found, 311.2197.

1-Hydroxy-1-(naphthalen-1-yl)heptan-3-one (26c)⁵⁵

88 mg, 69%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 8.01 (d, $J = 8.4$ Hz, 1H), 7.94–7.87 (m, 1H), 7.78 (t, $J = 8.8$ Hz, 1H), 7.69 (d, $J = 7.1$ Hz, 1H), 7.60–7.44 (m, 3H), 5.96 (dt, $J = 8.4, 2.9$ Hz, 1H), 3.47 (d, $J = 3.1$ Hz, 1H), 3.09–2.85 (m, 2H), 2.59–2.40 (m, 2H), 1.73–1.53 (m, 2H), 1.42–1.27 (m, 2H), 0.90 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 212.0, 138.5, 133.9, 130.0, 129.2, 128.2, 126.3, 125.7, 125.7, 123.1, 122.9, 67.0, 50.5, 43.6, 25.8, 22.4, 13.9. IR ν_{max} (solid/ cm^{-1}) 3451 (O-H), 2957 (C-H), 2931 (C-H), 2872 (C-H), 1706 (C=O), 1264, 1050, 800, 778.

1-((*tert*-Butyldimethylsilyl)oxy)-5-hydroxy-5-methylnon-8-en-3-one (27c)

81 mg, 54%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.80 (m, 1H), 4.98 (m, 2H), 3.88 (m, 2H), 3.82 (s, 1H), 2.68 (d, $J = 17.1$ Hz, 1H), 2.61 (m, 3H), 2.15–2.07 (m, 2H), 1.62–1.53 (m, 2H), 1.21 (s, 3H), 0.87 (s, 9H), 0.05 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 212.4, 138.8, 114.6, 71.7, 58.8, 52.9, 47.4, 41.3, 28.4, 26.9, 26.0, 18.4, -5.4. IR ν_{max} (solid/ cm^{-1}) 3498 (O-H), 2955 (C-H), 2930 (C-H), 2857 (C-H), 1702 (C=O), 1375, 1331, 1125, 835, 812. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{16}\text{H}_{32}\text{O}_3\text{SiNa}^+$, 323.2013; Found, 323.2014.

Ethyl 3-hydroxy-5-oxo-5-*p*-tolylpentanoate (28c)

97 mg, 77%, yellow solid, mp 86–87 °C $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.86 (d, $J = 7.8$ Hz, 2H), 7.27 (d, $J = 7.8$ Hz, 2H), 4.65 (m, 1H), 4.18 (q, $J = 7.1$ Hz, 2H), 3.61 (s, 1H), 3.24–3.16 (m, 2H), 2.62 (d, $J = 6.4$ Hz, 2H), 2.42 (s, 3H), 1.28 (t, $J = 7.1$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 199.3, 172.0, 144.7, 134.3, 129.5, 128.4, 64.9, 60.9, 44.2, 41.0, 21.8, 14.3. IR ν_{max} (solid/ cm^{-1}) 3451 (O-H), 2975 (C-H), 2957 (C-H), 2855 (C-H), 1731 (C=O), 1679 (C=O), 1606 (C=C), 1407, 1181, 1059, 810. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{14}\text{H}_{18}\text{O}_4\text{Na}^+$, 273.1097; Found, 274.1096.

6,6-Diethoxy-1-(2-fluorophenyl)-1-hydroxyhexan-3-one (29c)

125 mg, 84%, yellow oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.58–7.48 (m, 1H), 7.26–7.20 (m, 1H), 7.15 (td, $J = 7.5, 1.1$ Hz, 1H), 7.06–6.94 (m, 1H), 5.44 (m, 1H), 4.48 (t, $J = 5.3$ Hz, 1H), 3.70–3.54 (m, 3H), 3.54–3.42 (m, 2H), 2.91 (dd, $J = 17.4, 2.9$ Hz, 1H), 2.81 (dd, $J = 17.4, 9.2$ Hz, 1H), 2.64–2.46 (m, 2H), 1.92 (m, 2H), 1.18 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 211.0, 159.4 (d, $J_{\text{C-F}} = 245.4$ Hz), 129.9 (d, $J_{\text{C-F}} = 13.1$ Hz), 129.0 (d, $J_{\text{C-F}} = 8.2$ Hz), 127.3 (d, $J_{\text{C-F}} = 4.3$ Hz), 124.4 (d, $J_{\text{C-F}} = 3.4$ Hz), 115.2 (d, $J_{\text{C-F}} = 21.5$ Hz), 102.0, 64.3 (d, $J_{\text{C-F}} = 2.8$ Hz), 61.8, 61.8, 49.8, 38.2, 27.7, 15.3. IR ν_{max} (solid/ cm^{-1}) 3433 (O-H), 2974 (C-H), 2930 (C-H), 2897 (C-H), 1710 (C=O), 1487, 1372, 1119, 1055, 757. HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{16}\text{H}_{23}\text{NFO}_4\text{Na}^+$, 321.1473; Found, 321.1480.

Preparation of Aminoketones

The corresponding propargylic alcohol (0.5 mmol, 1 equiv) was dissolved in a mixture of toluene:MeOH (98:2, 0.5 mL), and $\text{PPh}_3\text{AuNTf}_2$ (8 mg, 2 mol%) was added into the reaction mixture. The mixture was stirred for 5 h and then the corresponding amine (0.5 mmol, 1 equiv.) was added and the reaction heated to 50 °C overnight. The solvent was removed in vacuo and the product was purified by column chromatography (EtOAc/Petrol).

7-((Phenylamino)tridecan-5-one (1da)

131 mg, 91%, pale brown oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.19–7.02 (m, 2H), 6.75–6.66 (m, 1H), 6.59 (m, 2H), 3.96–3.77 (m, 1H), 3.67 (s, 1H), 2.67 (dd, $J = 16.3, 5.0$ Hz, 1H), 2.55 (dd, $J = 16.3, 6.5$ Hz, 1H), 2.38 (t, $J = 7.4$ Hz, 2H), 1.53 (m, 4H), 1.36–1.17 (m, 10H), 0.88 (t, $J = 7.4$ Hz, 3H), 0.87 (t, $J = 7.0$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 210.7, 147.4, 129.5, 117.5, 113.5, 49.9, 47.1, 43.6, 35.4, 31.9, 29.3, 26.4, 25.8, 22.7, 22.4, 14.2, 14.0. IR ν_{max} (solid/ cm^{-1}) 3367 (N-H), 2924 (C-H), 2854 (C-H), 1704 (C=O), 1599 (C=C), 1498 (C=C), 746. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{32}\text{NO}^+$, 290.2478; Found, 290.2478.

7-((4-Fluorophenyl)amino)tridecan-5-one (1db)

133 mg, 87%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 6.89–6.84 (m, 2H), 6.56–6.51 (m, 2H), 3.79–3.71 (m, 1H), 2.63 (dd, $J = 16.4, 5.2$ Hz, 1H), 2.55 (dd, $J = 16.4, 6.2$ Hz, 1H), 2.38 (t, $J = 7.4$ Hz, 2H), 1.59–1.49 (m, 4H), 1.32–1.22 (m, 10H), 0.88 (t, $J = 7.0$ Hz, 3H), 0.87 (t, $J = 7.1$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 210.7, 155.9 (d, $J_{\text{C-F}} = 245.0$ Hz) 143.8 (d, $J_{\text{C-F}} = 1.5$ Hz), 115.9 (d, $J_{\text{C-F}} = 22.3$ Hz), 114.5 (d, $J_{\text{C-F}} = 7.4$ Hz), 50.9, 46.9, 43.7, 35.3, 31.9, 29.3, 26.4, 25.8, 22.7, 22.4, 14.2, 13.9. IR ν_{max} (solid/ cm^{-1}) 3361 (N-H), 2915 (C-H), 2822 (C-H), 1703 (C=O), 1601 (C=C), 1517 (C=C), 746. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{31}\text{FNO}^+$, 308.2384; Found, 308.2385.

7-((3,5-Dimethylphenyl)amino)tridecan-5-one (1dc)

150 mg, 95%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 6.35 (s, 1H), 6.23 (s, 2H), 3.80 (m, 1H), 3.59 (br s, 1H), 2.65 (dd, $J = 16.3, 4.8$ Hz, 1H), 2.54 (dd, $J = 16.3, 6.8$ Hz, 1H), 2.39 (m, 2H), 2.22 (s, 6H), 1.52 (m, 4H), 1.30 (m, 10H), 0.89 (t, $J = 7.2$ Hz, 3H), 0.88 (t, $J = 7.2$, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 210.8, 147.4, 139.1, 119.5, 111.4, 49.9, 47.2, 43.6, 35.4, 31.9, 29.3, 26.3, 25.9, 22.7, 22.4, 21.6, 14.2, 14.0. IR ν_{max} (solid/ cm^{-1}) 3387 (N-H), 2952 (C-H), 2853 (C-H), 1704 (C=O), 1597 (C=C), 1463 (C=C), 819. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{36}\text{NO}^+$, 318.2791; Found, 318.2797.

7-((4-Methoxyphenyl)amino)tridecan-5-one (1dd)

Propargylic alcohol **1a** (98 mg, 0.5 mmol, 1 equiv) was dissolved in a mixture of toluene:MeOH (98:2, 0.5 mL), and $\text{PPh}_3\text{AuNTf}_2$ (8 mg, 2 mol%) was added into the reaction mixture. The mixture was stirred for 5 h and then filtered through a silica pad. The solvent was removed in vacuo and anisidine (62 mg, 0.5 mmol, 1 equiv.) was added and the mixture was dissolved in toluene (0.2 mL) and heated to 50 °C

overnight. The solvent was removed in vacuo and the product was purified by column chromatography (EtOAc/Petrol) to give the amino ketone.

149 mg, 94%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 6.86–6.68 (m, 2H), 6.63–6.52 (m, 2H), 3.73 (s, 3H), 3.71 (m, 1H), 2.63 (dd, J = 16.2, 5.2 Hz, 1H), 2.53 (dd, J = 16.2, 6.4 Hz, 1H), 2.37 (t, J = 7.4 Hz, 2H), 1.60–1.46 (m, 4H), 1.37–1.22 (m, 10H), 0.87 (t, J = 7.4 Hz, 3H), 0.86 (t, J = 7.2, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 210.9, 152.3, 141.5, 115.2, 115.0, 55.9, 51.2, 47.0, 43.6, 35.3, 31.8, 29.3, 26.3, 25.8, 22.7, 22.3, 14.1, 13.9. IR ν_{max} (solid/ cm^{-1}) 3365 (N-H), 2925 (C-H), 1703 (C=O), 1508 (C=C), 1462 (C=C), 1233. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{34}\text{NO}_2^+$, 320.2584; Found, 320.2587.

7-((3-(Trifluoromethyl)phenyl)amino)tridecan-5-one (1df)

126 mg, 71%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.23 (t, J = 7.9 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.77 (s, 1H), 6.73 (dd, J = 8.2, 2.0 Hz, 1H), 3.97 (br s, 1H), 3.86–3.77 (m, 1H), 2.66 (dd, J = 16.6, 5.0 Hz, 1H), 2.59 (dd, J = 16.6, 6.1 Hz, 1H), 2.39 (t, J = 7.4 Hz, 2H), 1.61–1.49 (m, 4H), 1.35–1.22 (m, 10H), 0.89 (t, J = 7.3 Hz, 3H), 0.88 (t, J = 7.1, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 210.4, 147.6, 131.8 (q, $J_{\text{C-F}}$ = 31.6 Hz), 129.9, 124.4 (q, $J_{\text{C-F}}$ = 272.4 Hz), 116.1, 113.8 (q, $J_{\text{C-F}}$ = 3.9 Hz), 109.5 (q, $J_{\text{C-F}}$ = 3.9 Hz), 49.8, 46.6, 43.7, 35.2, 31.8, 29.3, 26.4, 25.8, 22.7, 22.4, 14.1, 13.9. IR ν_{max} (solid/ cm^{-1}) 3378 (N-H), 2925 (C-H), 2855 (C-H), 1704 (C=O), 1612 (C=C), 1339 (C=C), 1119. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{31}\text{F}_3\text{NO}^+$, 358.2353; Found, 358.2352.

7-(*o*-Tolylamino)tridecan-5-one (1dg)

80 mg, 53%, colourless oil, $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 7.10 (t, J = 8.3 Hz, 1H), 7.05 (d, J = 7.2 Hz, 1H), 6.66–6.57 (m, 2H), 3.91–3.83 (m, 1H), 2.70 (dd, J = 16.4, 4.8 Hz, 1H), 2.60 (dd, J = 16.4, 6.6 Hz, 1H), 2.40–2.37 (m, 2H), 2.12 (s, 3H), 1.62–1.57 (m, 2H), 1.57–1.49 (m, 2H), 1.35–1.23 (m, 10H), 0.89 (t, J = 7.3, 3H), 0.88 (t, J = 7.3, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 210.8, 145.2, 130.4, 127.3, 122.3, 116.8, 110.1, 49.6, 47.0, 43.7, 35.4, 31.9, 29.3, 26.4, 25.8, 22.7, 22.4, 17.7, 14.2, 14.0. IR ν_{max} (solid/ cm^{-1}) 3369 (N-H), 2924 (C-H), 2871 (C-H), 1705 (C=O), 1587 (C=C), 1489 (C=C), 767. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{34}\text{NO}^+$, 304.2635; Found, 304.2639.

7-(Quinolin-6-ylamino)tridecan-5-one (1dj)

86 mg, 51%, pale brown oil. $^1\text{H NMR}$ (600 MHz, CDCl_3) δ 8.59 (dd, J = 4.2, 1.5 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.85 (d, J = 9.0 Hz, 1H), 7.28–7.20 (m, 1H), 7.05 (dd, J = 9.0, 2.6 Hz, 1H), 6.69 (d, J = 2.5 Hz, 1H), 3.98–3.92 (m, 1H), 2.73 (dd, J = 16.6, 4.8 Hz, 1H), 2.63 (dd, J = 16.6, 6.4 Hz, 1H), 2.43–2.34 (m, 2H), 1.64–1.58 (m, 2H), 1.56–1.49 (m, 2H), 1.43 (m, 1H), 1.34–1.21 (m, 9H), 0.89 (t, J = 7.4 Hz, 3H), 0.87 (t, J = 7.3, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (151 MHz, CDCl_3) δ 210.6, 146.3, 145.3, 143.3, 133.9, 130.5, 130.3, 121.8, 121.5, 103.5, 49.9, 46.7, 43.8, 35.3, 31.9, 29.3, 26.4, 25.8, 22.69, 22.4, 14.2, 13.9. IR ν_{max} (solid/ cm^{-1}) 3380 (N-H), 2952 (C-H), 2923 (C-H), 1703 (C=O), 1620 (C=C), 1517 (C=C), 1377, 826. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{33}\text{N}_2\text{O}^+$, 341.2587; Found, 341.2584.

1-Phenyl-3-(phenylamino)nonan-1-one (5da)

143 mg, 93%, colourless oil, $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.92 (m, 2H), 7.59–7.51 (m, 1H), 7.50–7.42 (m, 2H), 7.20–7.13 (m, 2H), 6.74–6.66 (m, 1H), 6.62 (m, 2H), 4.03 (m, 1H), 3.77 (br s, 1H), 3.24 (dd, J = 16.6, 4.4 Hz, 1H), 3.13 (dd, J = 16.6, 6.9 Hz, 1H), 1.75–1.54 (m, 2H), 1.47 (m, 1H), 1.39 (m, 1H), 1.32–1.20 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 199.7, 147.4, 137.4, 133.3, 129.5, 128.8, 128.2, 117.5, 113.5, 50.2, 42.9, 35.6, 31.9, 29.4, 26.5, 22.7, 14.2. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{21}\text{H}_{28}\text{NO}^+$, 310.2165; Found, 310.2168.

1-Phenyl-3-(phenylamino)propan-1-one (7da)⁵⁹

82 mg, 73%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.95 (d, J = 7.7 Hz, 2H), 7.57 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.5 Hz, 2H), 7.18 (t, J = 7.4 Hz, 2H), 6.71 (t, J = 7.3 Hz, 1H), 6.65 (d, J = 7.8 Hz, 2H), 3.62 (t, J = 6.0 Hz, 2H), 3.29 (t, J = 6.0 Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 199.5, 147.9, 136.9, 133.5, 129.5, 128.8, 128.2, 117.7, 113.2, 38.9, 37.8. IR ν_{max} (solid/ cm^{-1}) 3403 (N-H), 3051 (C-H), 1675 (C=O), 1598 (C=C), 1504 (C=C), 1446.

1-Cyclohexyl-1-(phenylamino)heptan-3-one (14da)

127 mg, 89%, yellow oil; $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.14 (m, 2H), 6.65 (t, J = 6.8 Hz, 1H), 6.58 (d, J = 7.9 Hz, 2H), 3.72 (m, 1H), 2.62 (dd, J = 16.2, 5.0 Hz, 1H), 2.56 (dd, J = 16.2, 6.3 Hz, 1H), 2.38 (t, J = 7.4 Hz, 2H), 2.05–1.86 (m, 2H), 1.75 (m, 3H), 1.68–1.61 (m, 3H), 1.50 (m, 3H), 1.26 (m, 3H), 1.23–1.15 (m, 1H), 0.86 (t, J = 7.3 Hz, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 210.8, 147.8, 129.5, 117.2, 113.3, 54.7, 44.8, 43.4, 42.1, 29.7, 29.6, 26.6, 26.4, 25.9, 22.4, 14.0. IR ν_{max} (solid/ cm^{-1}) 3492 (O-H), 2921 (C-H), 2849 (C-H), 1702 (C=O), 1598 (C=C), 1446 (C=C), 745. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{19}\text{H}_{30}\text{NO}^+$, 288.2322; Found, 288.2329.

1,1-Diethoxy-6-(phenylamino)dodecan-4-one (25da)

93 mg, 51%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.15 (t, J = 7.4 Hz, 2H), 6.67 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 7.9 Hz, 2H), 4.45 (t, J = 5.2 Hz, 1H), 3.85–3.79 (m, 1H), 3.65 (br s, 1H), 3.63–3.56 (m, 2H), 3.49–3.40 (m, 2H), 2.67 (dd, J = 16.2, 5.0 Hz, 1H), 2.58 (dd, J = 16.2, 6.3 Hz, 1H), 2.49 (t, J = 7.2 Hz, 2H), 1.86 (m, 2H), 1.53 (m, 2H), 1.44–1.37 (m, 1H), 1.27 (m, 9H), 1.17 (t, J = 7.0 Hz, 6H), 0.86 (t, J = 6.8 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 209.9, 147.4, 129.5, 117.5, 113.5, 102.1, 61.8, 50.0, 47.27, 38.6, 35.4, 31.9, 29.4, 27.6, 26.4, 22.7, 15.4, 14.2. IR ν_{max} (solid/ cm^{-1}) 3355 (N-H), 2914 (C-H), 2848 (C-H), 1698 (C=O), 1595 (C=C), 1469 (C=C), 1367, 1054 746. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{22}\text{H}_{38}\text{NO}_3^+$, 290.2478; Found, 290.2478.

Preparation of Heterocycles

The corresponding propargylic alcohol (0.5 mmol, 1 equiv.) and aniline (0.5 mmol, 1 equiv.) were dissolved in CHCl_3 (0.5 mL) and oven-dried molecular sieves were added to the mixture followed by $\text{PPh}_3\text{AuNTf}_2$ (8 mg, 2 mol%). The reaction was stirred at room temperature until completion (TLC). Once the reaction was complete, Et_2O (1 mL) and NaCNBH_3 (62 mg, 1 mmol, 2 equiv.) were added and the reaction was stirred for 2 h at 0 °C. After this time the mixture was filtered and the solvent removed in vacuo. The residue was dissolved in CH_2Cl_2 :TFA (50:1, 2.5 mL) and NaBH_4 (46 mg, 1.25 mmol, 2.5 equiv.)

was added. The solution was stirred overnight. The reaction was then quenched with NH_4Cl and extracted with Et_2O . The organic layer was concentrated in vacuo and the product was purified by column chromatography (EtOAc /Petrol).

2-Methyl-1-(1-phenylpyrrolidin-2-yl)propan-2-ol (6ea)

After aniline addition the reaction was stirred for 18h.

78 mg, 73%, colourless oil. $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.23 (dd, $J = 8.5, 7.3$ Hz, 2H), 6.66 (m, 3H), 4.00–3.92 (m, 1H), 3.40 (m, 1H), 3.20–3.07 (m, 1H), 2.08–1.97 (m, 4H), 1.85 (d, $J = 14.4$ Hz, 1H), 1.48 (dd, $J = 14.4, 10.3$ Hz, 1H), 1.36 (s, 3H), 1.31 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 147.1, 129.4, 115.4, 112.2, 71.0, 54.9, 47.9, 45.7, 32.5, 30.6, 30.5, 23.4. IR ν_{max} (solid/ cm^{-1}) 3405 (O-H), 2965 (C-H), 2928 (C-H), 1705, 1596 (C=C), 1504 (C=C), 1360, 745, 693. HRMS (ESI-TOF) m/z : $[\text{M}]^+$ Calcd for $\text{C}_{14}\text{H}_{21}\text{NO}^+$, 219.1618; Found, 219.1617.

1-(1-(4-Methoxyphenyl)pyrrolidin-2-yl)-2-methylpropan-2-ol (6ed)

After aniline addition the reaction was stirred for 48h.

93 mg, 75%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 6.93–6.80 (m, 2H), 6.66 (d, $J = 9.0$ Hz, 2H), 3.93–3.85 (m, 1H), 3.75 (s, 3H), 3.46–3.35 (m, 1H), 3.11–3.05 (m, 1H), 2.10–1.93 (m, 4H), 1.88–1.81 (m, 1H), 1.50–1.43 (m, 1H), 1.33 (s, 3H), 1.30 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 151.1, 142.5, 115.2, 113.7, 71.0, 56.1, 55.7, 48.9, 46.0, 32.6, 30.8, 30.4, 23.6. IR ν_{max} (solid/ cm^{-1}) 3420 (O-H), 2965 (C-H), 2929 (C-H), 1708, 1611 (C=C), 1512 (C=C), 1364, 1275, 813. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{24}\text{NO}_2^+$, 250.1802; Found, 250.1804.

2-Methyl-1-(1-(3-(trifluoromethyl)phenyl)pyrrolidin-2-yl)propan-2-ol (6ef)

After aniline addition the reaction was stirred for 48h.

95 mg, 67%, colourless oil, $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 6.93–6.80 (m, 2H), 6.66 (d, $J = 9.0$ Hz, 2H), 3.93–3.85 (m, 1H), 3.75 (s, 3H), 3.46–3.35 (m, 1H), 3.11–3.05 (m, 1H), 2.10–1.93 (m, 4H), 1.88–1.81 (m, 1H), 1.50–1.43 (m, 1H), 1.33 (s, 3H), 1.30 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 146.9, 131.5 (q, $J_{\text{C-F}} = 31.3$ Hz), 129.6, 124.8 (q, $J_{\text{C-F}} = 272.4$ Hz), 115.0, 111.6 (q, $J_{\text{C-F}} = 3.3$ Hz), 108.5 (q, $J_{\text{C-F}} = 3.8$ Hz), 71.0, 55.7, 48.9, 46.0, 32.6, 30.8, 30.4, 23.6. IR ν_{max} (solid/ cm^{-1}) 3434 (O-H), 2969 (C-H), 2930 (C-H), 1710, 1609 (C=C), 1458 (C=C), 1161, 1119, 698. HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{15}\text{H}_{21}\text{F}_3\text{NO}^+$, 288.1570; Found, 288.1570.

1-(2-Fluorophenyl)-2-(1-phenylpyrrolidin-2-yl)ethan-1-ol (29ea)

After aniline addition the reaction was stirred for 48h.

78 mg, 55%, colourless oil, only one diastereoisomer was observed. $^1\text{H NMR}$ (700 MHz, CDCl_3) δ 7.56–7.49 (m, 1H), 7.25–7.21 (m, 3H), 7.16–7.12 (m, 1H), 7.04–6.99 (m, 1H), 6.69 (m, 2H), 6.67 (m, 1H), 5.17–5.10 (m, 1H), 4.14 (m, 1H), 3.41 (m, 1H), 3.21–3.14 (m, 1H), 2.21–2.16 (m, 1H), 2.09–2.00 (m, 4H), 1.99–1.93 (m, 1H), 1.61–1.58 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (176 MHz, CDCl_3) δ 159.5 (d, $J_{\text{C-F}} = 244.9$ Hz), 147.3, 132.1 (d, $J_{\text{C-F}} = 13.2$ Hz), 129.4, 129.0 (d, $J_{\text{C-F}} = 8.2$ Hz), 127.0 (d, $J = 4.3$ Hz), 124.5 (d, $J = 3.4$ Hz), 115.6, 115.4

(d, $J = 21.7$ Hz), 112.1, 66.7, 55.8, 48.2, 41.2, 30.5, 23.4. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3397 (O-H), 2958 (C-H), 2928 (C-H), 1710, 1642 (C=C), 1554 (C=C), 1454, 756. **HRMS** (ESI-TOF) m/z : [M+H]⁺ Calcd for C₁₈H₂₁FNO⁺, 286.1602; Found, 286.1602.

(*R,S*)-2-(4-Chlorophenyl)-1-((*R,S*)-1-phenylpyrrolidin-2-yl)propan-2-ol (30ea)

After aniline addition the reaction was stirred for 48h.

99 mg, 63%, colourless oil, only one diastereoisomer was observed. **¹H NMR** (600 MHz, CDCl₃) δ 7.46–7.37 (m, 2H), 7.35–7.30 (m, 2H), 7.24–7.11 (m, 2H), 6.66 (t, $J = 7.3$ Hz, 1H), 6.62–6.50 (m, 2H), 3.94–3.84 (m, 1H), 3.39–3.32 (m, 1H), 3.07 (td, $J = 9.0, 7.4$ Hz, 1H), 2.11 (dd, $J = 14.4, 2.3$ Hz, 1H), 1.95–1.80 (m, 2H), 1.76 (dd, $J = 14.4, 9.3$ Hz, 1H), 1.63 (s, 3H), 1.62–1.55 (m, 2H). **¹³C{¹H} NMR** (176 MHz, CDCl₃) δ 147.4, 146.5, 132.7, 129.3, 128.5, 126.6, 116.0, 112.7, 74.2, 54.8, 48.3, 46.8, 31.6, 31.6, 23.3. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3406 (O-H), 2966 (C-H), 2925 (C-H), 1712, 1597 (C=C), 1504 (C=C), 1363, 748. **HRMS** (ESI-TOF) m/z : [M+H]⁺ Calcd for C₁₉H₂₃NOCl⁺, 316.1463; Found, 316.1465.

2-Methyl-1-(1-phenylpiperidin-2-yl)propan-2-ol (31ea)

After aniline addition the reaction was stirred for 18h.

82 mg, 71%, colourless oil, **¹H NMR** (600 MHz, CDCl₃) δ 7.28–7.24 (m, 2H), 7.03 (br d, $J = 8.0$ Hz, 2H), 6.83 (d, $J = 7.3$ Hz, 1H), 4.24–4.16 (m, 1H), 3.70 (br s, 1H), 3.51–3.46 (m, 1H), 3.42–3.30 (m, 1H), 2.26 (dd, $J = 14.6, 9.7$ Hz, 1H), 1.92–1.83 (m, 1H), 1.73 (m, 1H), 1.63 (m, 2H), 1.55–1.38 (m, 3H), 1.25 (s, 3H), 1.23 (s, 3H). **¹³C{¹H} NMR** (176 MHz, CDCl₃) δ 150.4, 129.4, 119.4, 117.5, 70.8, 53.1, 43.4, 40.7, 31.2, 29.2, 28.1, 23.2, 19.9. **IR** $\nu_{\max}$ (solid/cm⁻¹) 3393 (O-H), 2967 (C-H), 2927 (C-H), 1596 (C=C), 1498 (C=C), 1154, 1092, 752, 692. **HRMS** Found 234.1851, [C₁₅H₂₃NO+H]⁺ requires 234.1852. **HRMS** (ESI-TOF) m/z : [M+H]⁺ Calcd for C₁₅H₂₄NO⁺, 234.1852; Found, 232.1851.

Conflicts of interest

There are no conflicts of interest to declare.

Acknowledgements

We would like to thank the Leverhulme Trust for providing a grant (RPG-2017-221) to support this work.

Supporting Information

Complete optimization tables, details of computational methods and coordinates for all calculated intermediates, chiral HPLC traces for compounds (**S**)-**9c** and (**1S,3R**)-**9bd**, and ¹H and ¹³C spectra for all compounds.

Notes and references

*All propargylic alcohols are numbered as **Na**, and all other compounds are labelled with the number of the propargylic alcohol from which they are derived. Thus, all aminoalcohols are numbered **NbX** (where X is a letter used to denote the nitrogen substituent derived from the aniline), all 3-hydroxyketones **Nc**,

all 3-aminoketones **NdX**, and all saturated heterocycles **NeX** (where X in all cases denotes the nitrogen substituent derived from the aniline).

1 a) S. H. Cho, J. Y. Kim, J. Kwak and S. Chang, Recent advances in the transition metal-catalyzed twofold oxidative C–H bond activation strategy for C–C and C–N bond formation. *Chem. Soc. Rev.*, **2011**, *40*, 5068–5083. b) S. K. Ghorai, V. G. Gopalsamuthiram, A. M. Jawalekar R. E. Patre and S. Pal, Iron catalyzed C–N bond formation, *Tetrahedron*, **2017**, *73*, 1769–1794. c) L. Q. Nguyen and R. R. Knowles, Catalytic C–N Bond-Forming Reactions Enabled by Proton-Coupled Electron Transfer Activation of Amide N–H Bonds, *ACS Catal.*, **2016**, *6*, 2894–2903.

2 a) L. Huang, M. Arndt, K. Gooßen H. Heydt and L. J. Gooßen, Late Transition Metal-Catalyzed Hydroamination and Hydroamidation, *Chem. Rev.*, **2015**, *115*, 2596–2697. b) R. Severin and S. Doye, The catalytic hydroamination of alkynes, *Chem. Soc. Rev.*, **2007**, *36*, 1407–1420. c) T. E. Müller, K. C. Hultsch, M. Yus, F. Foubelo and M. Tada, Hydroamination: Direct addition of amines to Alkenes and Alkynes, *Chem. Rev.*, **2008**, *108*, 3795–3892. d) A. S. K. Hashmi, *Gold Bull.*, Homogeneous Gold Catalysts and Alkynes: A Successful Liaison, **2003**, *36*, 3–9. e) A. J. Musacchio, B. C. Lainhart, X. Zhang, S. G. Naguib, T. C. Sherwood and R. R. Knowles, Catalytic intermolecular hydroaminations of unactivated olefins with secondary alkyl amines, *Science*, **2017**, *355*, 727–730. f) Y. Zhang, J. P. Donahue and C. Li, Gold(III)-Catalyzed Double Hydroamination of o-Alkynylaniline with Terminal Alkynes Leading to N-Vinylindoles, *Org. Lett.*, **2007**, *9*, 627–630. g) V. Lavallo, G. D. Frey, B. Donnadieu, M. Soleilhavoup and G. Bertrand, Homogeneous Catalytic Hydroamination of Alkynes and Allenes with Ammonia, *Angew. Chem. Int. Ed.*, **2008**, *47*, 5224–5228.

3 a) M. Tokunaga, M. Eckert and Y. Wakatsuki, Ruthenium-Catalyzed Intermolecular Hydroamination of Terminal Alkynes with Anilines : A Practical Synthesis of Aromatic Ketimines, *Angew. Chem. Int. Ed.*, **1999**, *38*, 3222–3225. b) A. Tillack, I. G. Castro, C. G. Hartung and M. Beller, Anti-Markovnikov Hydroamination of Terminal Alkynes, *Angew. Chem. Int. Ed.*, **2002**, *41*, 2541–2543. c) C. Li, R. K. Thomson, B. Gillon, B. O. Patrick and L. L. Schafer, Amidate complexes of titanium and zirconium: a new class of tunable precatalysts for the hydroamination of alkynes, *Chem. Commun.*, **2003**, 2462–2463.

4 a) X. Liu and C. Che, Highly Efficient and Regioselective Platinum(II)-Catalyzed Tandem Synthesis of Multiply Substituted Indolines and Tetrahydroquinolines, *Angew. Chem. Int. Ed.*, **2009**, *48*, 2367–2371. b) A. S. K. Hashmi and M. Buehrle, Gold Catalyzed addition of X–H Bonds to C–C multiple Bonds, *Aldrichim. Acta*, **2010**, *43*, 27–33. c) E. K. J. Lui and L. L. Schafer, Facile Synthesis and Isolation of Secondary Amines via a Sequential Titanium(IV)-Catalyzed Hydroamination and Palladium-catalyzed hydrogenation, *Adv. Synth. Catal.*, **2016**, *358*, 713–718. d) J. C. Yim, J. A. Bexrud, R. O. Ayinla, D. C. Leitch and L. L. Schafer, Bis(amidate)bis(amido) Titanium Complex: A Regioselective Intermolecular Alkyne Hydroamination Catalyst, *J. Org. Chem.*, **2014**, *79*, 2015–2028. e) C. Brahms, P. Tholen, W. Saak and S. Doye, An (Aminopyrimidinato)titanium Catalyst for the Hydroamination of Alkynes and Alkenes *Eur. J. Org. Chem.*, **2013**, 7583–7592.

5 a) L. L. Anderson, J. Arnold and R. G. Bergman, Catalytic Hydroamination of Alkynes and Norbornene with Neutral and Cationic Tantalum Imido Complexes, *Org. Lett.*, **2004**, *6*, 2519–2522. b) H. Duan, S. Sengupta, J. L. Petersen, N. G. Akhmedov and X. Shi, Triazole–Au(I) Complexes: A New Class of Catalysts with Improved Thermal Stability and Reactivity for Intermolecular Alkyne Hydroamination, *J. Am. Chem. Soc.*, **2009**, *131*, 12100–12102. c) K. D. Hesp and M. Stradiotto, Stereo- and Regioselective Gold-

Catalyzed Hydroamination of Internal Alkynes with Dialkylamines, *J. Am. Chem. Soc.*, **2010**, *132*, 18026–18029.

6 a) A. Leyva and A. Corma, Reusable Gold(I) Catalysts with Unique Regioselectivity for Intermolecular Hydroamination of Alkynes, *Adv. Synth. Catal.*, **2009**, *351*, 2876–2886. b) E. Kumaran and W. K. Leong, Organometallics, Rhodium(III)-Catalyzed Hydroamination of Aromatic Terminal Alkynes with Anilines, **2012**, *31*, 1068–1072. c) Q. Chen, L. Lv, M. Yu, Y. Shi, Y. Li, G. Pang and C. Cao, Simple, efficient and reusable Pd–NHC catalysts for hydroamination, *RSC Adv.*, **2013**, *3*, 18359–18366.

7 a) J. C. Yim and L. L. Schafer, Efficient Anti-Markovnikov-Selective Catalysts for Intermolecular Alkyne Hydroamination: Recent Advances and Synthetic Applications, *Eur. J. Org. Chem.*, **2014**, 6825–6840. b) M. A. Esteruelas, A. M. Lopez, A. C. Mateo and E. Oñate, New Half-Sandwich Alkyl, Aryl, Aryloxide, and Propargyloxide Titanium(IV) Complexes Containing a Cyclopentadienyl Ligand with a Pendant Ether Substituent: Behavior and Influence in the Hydroamination of Alkynes of the Ether Group, *Organomet. Chem.*, **2006**, *25*, 1448–1460..

8 a) S. Kramer, K. Dooleweerd, A. T. Lindhardt, M. Rottlander and T. Skrydstrup, Highly Regioselective Au(I)-Catalyzed Hydroamination of Ynamides and Propiolic Acid Derivatives with Anilines, *Org. Lett.*, **2009**, *11*, 4208–4211. b) Y. Kong, L. Yu, Y. Cui and J. Cao, Synthesis of *N*-Sulfonylamidines by Catalyst-Free Hydroamination of Ynamides and Amines, *Synthesis*, **2014**, *46*, 183–188. c) T. Ishikawa, T. Sonehara, M. Minakawa and M. Kawatsura, Copper-Catalyzed Intermolecular Hydroamination of Internal Alkynes with Anilines and Amines, *Org. Lett.*, **2016**, *18*, 1422–1425.

9 a) N. Shwarz, K. Alex, I. A. Sayyed, V. Khedkar, A. Tillack and M. Beller, Titanium-Catalyzed Hydroamination of Propargyl Alcohol Derivatives: Synthesis of 3-Silyloxy-2-methylindoles via Hydrohydrazination, *Synlett*, **2007**, 1091–1095; see also reference 4d. b) Cachi, G. Fabrizi, A. Goggiamani and A. Lazzetti, Construction of the 1,5-Benzodiazepine Skeleton from o-Phenylendiamine and Propargylic Alcohols via a Domino Gold-Catalyzed Hydroamination/Cyclization Process, *Org. Lett.*, **2016**, *18*, 3511–3513. c) Y. Kumar, G. Kumar, T. Reddy, B. Sridhar and M. Reddy, Synthesis of 3-Sulfonylamino Quinolines from 1-(2-Aminophenyl) Propargyl Alcohols through a Ag(I)-Catalyzed Hydroamination, (2 + 3) Cycloaddition, and an Unusual Strain-Driven Ring Expansion, *Org. Lett.*, **2015**, *17*, 2226–2229.

10 a) J. Mahatthananchai, A. M. Dumas and J. W. Bode, Catalytic Selective Synthesis, *Angew. Chem. Int. Ed.*, **2012**, *51*, 10954–10990. b) T. Shimbayashi, G. Matsushita, A. Nanya, A. Eguchi, K. Okamoto and K. Ohe, Divergent Catalytic Approach from Cyclic Oxime Esters to Nitrogen-Containing Heterocycles with Group 9 Metal Catalysts, *ACS Catal.*, **2018**, *8*, 7773–7780. c) R. Oost, J. D. Neuhaus, A. Misale, R. Meyrelles, L. F. Veiros and N. Maulide, Catalyst-dependent selectivity in sulfonium ylide cycloisomerization reactions, *Chem. Sci.*, **2018**, *9*, 7091–7095.

11 a) Y. Zhu, L. Sun, P. Lu and Y. Wang, Recent Advances on the Lewis Acid-Catalyzed Cascade Rearrangements of Propargylic Alcohols and Their Derivatives, *ACS Catal.*, **2014**, *9*, 1911–1925. b) P. Substi and R. Y. Nishibayashi, Transition-Metal-Catalyzed Enantioselective Propargylic Substitution Reactions of Propargylic Alcohol Derivatives with Nucleophiles, *Synthesis*, **2012**, *44*, 489–503. c) Y. Liu, G. Wu and Y. Cui, Ag/CNT-catalyzed hydroamination of activated alkynes with aromatic amines, *Appl. Organomet. Chem.*, **2013**, *27*, 206–208. d) B. J. Ayers and P. W. H. Chan, Harnessing the Versatile Reactivity of Propargyl Alcohols and their Derivatives for Sustainable Complex Molecule Synthesis, *Synlett*, **2015**, *26*, 1305–1339.

12 a) S. Liao, A. Porta, X. Cheng, X. Ma, G. Zanoni and L. Zhang, Bifunctional Ligand Enables Efficient Gold-Catalyzed Hydroalkenylation of Propargylic Alcohol, *Angew. Chem. Int. Ed.*, **2018**, *57*, 8250–8254. b) J. Jin, Y. Luo, C. Zhou, X. Chen, Q. Wen, P. Lu and Y. Wang, Synthesis of Indeno[1,2-*c*]furans via a Pd-Catalyzed Bicyclization of 2-Alkynyl iodobenzene and Propargylic Alcohol, *J. Org. Chem.*, **2012**, *77*, 11368–11371. c) R. Dorel and A. M. Echavarren, Ready Access to the Echinopines Skeleton via Gold(I)-Catalyzed Alkoxy cyclizations of Enynes, *J. Org. Chem.*, **2016**, *81*, 8444–8454. d) V. Laserna, C. Jeapes Rojas and T. D. Sheppard, Gold-Catalyzed Hydrophenoxylation of Propargylic Alcohols and Amines: Synthesis of Phenyl Enol Ethers, *Org. Lett.*, **2019**, *21*, 4443–4447.

13 a) H. Yuan, Y. Zheng and J. Zhang, Understanding the Mechanism of the Lewis Acid Promoted [3 + 2] Cycloaddition of Propargylic Alcohol and α -OxoKetene Dithioacetals, *J. Org. Chem.*, **2016**, *81*, 1989–1997. b) Y. Nagashima, K. Hirano, R. Takita and M. Uchiyama, *Trans* -Diborylation of Alkynes: Pseudo -Intramolecular Strategy Utilizing a Propargylic Alcohol Unit, *J. Am. Chem. Soc.*, **2014**, *136*, 8532–8535. c) D. Qian, L. Wu, Z. Lin and J. Sun, Organocatalytic synthesis of chiral tetrasubstituted allenes from racemic propargylic alcohols, *Nat. Commun.*, **2017**, *8*, 567. d) M. Ikeda, Y. Miyake and Y. Nishibayashi, Cooperative Catalytic Reactions Using Organocatalysts and Transition Metal Catalysts: Propargylic Allylation of Propargylic Alcohols with α , β -Unsaturated Aldehydes, *Organometallics*, **2012**, *31*, 3810–3813.

14 a) M. N. Pennell, M. G. Unthank, P. Turner and T. D. Sheppard, A General Procedure for the Synthesis of Enones via Gold-Catalyzed Meyer-Schuster Rearrangement of Propargylic Alcohols at Room Temperature, *J. Org. Chem.*, **2011**, *76*, 1476–1482. b) M. N. Pennell, P. G. Turner and T. D. Sheppard, Gold- and Silver-Catalyzed Reactions of Propargylic Alcohols in the Presence of Protic Additives, *Chem. Eur. J.*, **2012**, *18*, 4748–4758.

15 a) M. N. Pennell, R. W. Foster, P. G. Turner, H. C. Hailes, C. J. Tame and T. D. Sheppard, Gold catalysed synthesis of 3-alkoxyfurans at room temperature, *Chem. Commun.*, **2014**, *50*, 1302–1304. b) P. Tharra and B. Baire, Regioselective, cascade [3+2] annulation of β -naphthols (resorcinols) with *Z*-enoate propargylic alcohols: a novel entry for the synthesis of complex naphtho(benzo)furans, *Chem. Commun.*, **2016**, *52*, 14290–14293. c) A. Aponick, C. Li, J. Malinge and E. F. Marques, An Extremely Facile Synthesis of Furans, Pyrroles, and Thiophenes by the Dehydrative Cyclization of Propargyl Alcohols, *Org. Lett.*, **2009**, *11*, 4624–4627. d) K.-G. Ji, H.-T. Zhu, F. Yang, X.-Z. Shu, S.-C. Zhao, X.-Y. Liu, A. Shaukat and Y.-M. Liang, A Novel Iodine-Promoted Tandem Cyclization: An Efficient Synthesis of Substituted 3,4-Diodoheterocyclic Compounds, *Chem. Eur. J.* **2010**, *16*, 6151–6154.

16 a) S. Sun, B. Wang, N. Gu, J. Yu and J. Cheng, Palladium-Catalyzed Arylcarboxylation of Propargylic Alcohols with CO₂ and Aryl Halides: Access to Functionalized α -Alkylidene Cyclic Carbonates, *Org. Lett.*, **2017**, *19*, 1088–1091. b) Y. Kayaki, M. Yamamoto and T. Ikariya, *N*-Heterocyclic Carbenes as Efficient Organocatalysts for CO₂ Fixation Reactions, *Angew. Chem. Int. Ed.*, **2009**, *48*, 4194–4197.

17 a) Q. Song, Z. Zhou, M. Wang, K. Zhang, P. Liu and J. Xun, Thermodynamically Favorable Synthesis of 2-Oxazolidinones through Silver-Catalyzed Reaction of Propargylic Alcohols, CO₂, and 2-Aminoethanols, *ChemSusChem*, **2016**, *9*, 2054–2058. b) Y. Gu, Q. Zhang, Z. Duan, J. Zhang and S. Zhang, Ionic Liquid as an Efficient Promoting Medium for Fixation of Carbon Dioxide: A Clean Method for the Synthesis of 5-Methylene-1,3-oxazolidin-2-ones from Propargylic Alcohols, Amines, and Carbon Dioxide Catalyzed by Cu(I) under Mild Conditions, *J. Org. Chem.*, **2005**, *70*, 7376–7380. c) Y.-P. Han, X.-R. Song, Y.-F. Qiu, H.-R.

Zhang, L.-H. Li, D.-P. Jin, X.-Q. Sun, X.-Y. Liu, and Y.-M. Liang, Lewis Acid Catalyzed [4 + 3] Cycloaddition of Propargylic Alcohols with Azides, *Org. Lett.* **2016**, *185*, 940-943.

18 a) S. M. Gibson, J. M. D'Oyley, J. I. Higham, K. Sanders, V. Laserna, A. E. Aliev and T. D. Sheppard, Dihalohydration of Alkynols: A Versatile Approach to Diverse Halogenated Molecules, *Eur. J. Org. Chem.*, **2018**, 4018–4028. b) J. M. D'Oyley, A. E. Aliev and T. D. Sheppard, Regioselective Dihalohydration Reactions of Propargylic Alcohols: Gold-Catalyzed and Non-catalyzed Reactions, *Angew. Chem. Int. Ed.*, **2014**, *53*, 10747–10750.

19 L. Ricard and F. Gagosz, Phosphine Gold(I) Bis-(trifluoromethanesulfonyl) imidate Complexes as New Highly Efficient and Air-Stable Catalysts for the Cycloisomerization of Enynes, *Org. Lett.*, **2005**, *7*, 4133–4136.

20 a) L. Lefort, F. L. Van Delft and G. De Vries, Enantio- and diastereoselective synthesis of γ -amino alcohols, *Chem. Commun.*, **2015**, *51*, 14462–14464. b) T. A. Davis, P. R. Chopade and R. A. Flowers, Reduction of β -Hydroxyketones by $\text{SmI}_2/\text{H}_2\text{O}/\text{Et}_3\text{N}$ *Org. Lett.*, **2005**, *7*, 119–122.

21 P. C. Young, S. L. J. Green, G. M. Rosair and A.-L. Lee, Deactivation of gold(I) catalysts in the presence of thiols and amines – characterisation and catalysis, *Dalton Trans.* **2013**, *42*, 9645-9653.

22 J. M. M. Verkade, L. J. C. Van Hemert, P. J. L. M. Quaedflieg, P. L. Alsters, L. Van Delft and F. P. J. T. Rutjes, Mild and efficient deprotection of the amine protecting *p*-methoxyphenyl (PMP) group, *Tetrahedron Lett.*, **2006**, *47*, 8109–8113.

23 M. N. Pennell, M. P. Kyle, S. M. Gibson, L. Male, P. G. Turner, R. S. Grainger and T. D. Sheppard, Intercepting the Gold-Catalysed Meyer–Schuster Rearrangement by Controlled Protodemetalation: A Regioselective Hydration of Propargylic Alcohols, *Adv. Synth. Catal.*, **2016**, *358*, 1519–1525.

24 a) P. Nuhant, C. Allais and W. R. Roush, Diisopinocampheylborane-Mediated Reductive Aldol Reactions: Highly Enantio- and Diastereoselective Synthesis of *syn* Aldols from *N*-Acryloylmorpholine, *Angew. Chem. Int. Ed.*, **2013**, *52*, 8703–8707. b) D. A. Evans, J. V. Nelson, E. Vogel and T. R. Taber, Stereoselective Aldol Condensations via Boron Enolates, *J. Am. Chem. Soc.*, **1981**, *103*, 3099–3111.

25 a) P. M. Murray, F. Bellany, L. Benhamou, D.-K. Bučar, A. B. Tabor and T. D. Sheppard, The application of design of experiments (DoE) reaction optimisation and solvent selection in the development of new synthetic chemistry, *Org. Biomol. Chem.*, **2016**, *14*, 2373–2384. b) D. Prat, A. Wells, J. Hayler, H. Sneddon, C. R. McElroy, S. Abou-Shehade and P. J. Dunn, CHEM21 selection guide of classical- and less classical-solvents, *Green Chem.*, **2016**, *18*, 288–296.

26 a) R. Tao, Y. Yin, Y. Duan, Y. Sun, Y. Sun and F. Cheng, $\text{Fe}(\text{OTf})_3$ -catalyzed tandem Meyer-Schuster rearrangement/ Intermolecular hydroamination of 3-aryl propargyl alcohols for the synthesis of acyclic β -Aminoketones, *Tetrahedron*, **2017**, *73*, 1762–1768. b) S. Kim, S. Kang, G. Kim and Y. Lee, Copper-Catalyzed Aza-Michael Addition of Aromatic Amines or Aromatic Aza-Heterocycles to α,β -Unsaturated Olefins, *J. Org. Chem.*, **2016**, *81*, 4048–4057.

27 a) G. Barker, D. G. Johnson, P. C. Young, S. A. Macgregor and A.-L. Lee, Chirality Transfer in Gold (I)-Catalysed Direct Allylic Etherifications of Unactivated Alcohols: Experimental and Computational Study, *Chem Eur. J.*, **2015**, *21*, 13748–13757. b) P. Mukherjee and R. A. Widenhoefer, Gold (I)-Catalyzed

Intramolecular Amination of Allylic Alcohols With Alkylamines, *Org. Lett.*, **2011**, *13*, 1334–1337. c) P. Mukherjee and R. A. Widenhoefer, Gold(I)-Catalyzed Enantioselective Intramolecular Dehydrative Amination of Allylic Alcohols with Carbamates, *Angew. Chem. Int. Ed.*, **2012**, *51*, 1405–1407. d) P. C. Young, N. A. Schopf and A.-L. Lee, Gold(I)-catalysed direct allylic etherification of unactivated alcohols, *Chem. Commun.*, **2013**, *49*, 4262–4264. e) L. Herkert, S. L. J. Green, G. Barker, D. G. Johnson, P. C. Young, S. A. Macgregor and A.-L. Lee, Gold (I)-Catalysed Direct Thioetherifications Using Allylic Alcohols: an Experimental and Computational Study, *Chem. Eur. J.*, **2014**, *20*, 11540–11548. f) T. Ghebregiorgis, B. Biannic, B. H. Kirk, D. H. Ess and A. Aponick, The Importance of Hydrogen Bonding to Stereoselectivity and Catalyst Turnover in Gold-Catalyzed Cyclization of Monoallylic Diols, *J. Am. Chem. Soc.*, **2012**, *134*, 16307–16318.

28 D. Boyall, D. E. Frantz and E. M. Carreira, Efficient Enantioselective Additions of Terminal Alkynes and Aldehydes under Operationally Convenient Conditions, *Org. Lett.*, **2002**, *4*, 2605–2606.

29 a) X. Liu, Z. Guo, S. S. Dong, X. Li and C. Che, Highly Efficient and Diastereoselective Gold (I)-Catalyzed Synthesis of Tertiary Amines from Secondary Amines and Alkynes: Substrate Scope and Mechanistic Insights, *Chem. Eur. J.*, **2011**, *17*, 12932–12945. b) M. Katari, M. N. Rao, G. Rajaraman and P. Ghosh, Computational Insight into a Gold(I) N-Heterocyclic Carbene Mediated Alkyne Hydroamination Reaction, *Inorg. Chem.*, **2012**, *51*, 5593–5604. c) G. Ciancaleoni, S. Rampino, D. Zuccaccia, F. Tarantelli, P. Belanzoni and L. Belpassi, An ab Initio Benchmark and DFT Validation Study on Gold(I)-Catalyzed Hydroamination of Alkynes, *J. Chem. Theory Comput.*, **2014**, *10*, 1021–1034. d) A. Couce-Rios and G. Ujaque, Hydroamination of C–C Multiple Bonds with Hydrazine Catalyzed by N-Heterocyclic Carbene–Gold(I) Complexes: Substrate and Ligand Effects, *ACS Catal.*, **2015**, *5*, 815–829.

30 a) O. Seppanen, M. Muuronen and J. Helaja, Gold-Catalyzed Conversion of Aryl- and Alkyl-Substituted 1-(*o*-Aminophenyl)-2-propyn-1-ones to the Corresponding 2-Substituted 4-Quinolones, *Eur. J. Org. Chem.*, **2014**, 4044–4052. b) C. A. Gaggioli, G. Ciancaleoni, L. Biasiolo, G. Bistoni, D. Zuccaccia, L. Belpassi and F. Tarantelli, Anomalous ligand effect in gold(I)-catalyzed intramolecular hydroamination of alkynes, *Chem. Commun.*, **2015**, *51*, 5990–5993. c) G. Ciancaleoni, D. Zuccaccia, D. Chimica, F. Ambiente, U. Udine and V. Cotoni, Cyclization of 2-Alkynyldimethylaniline on Gold(I) Cationic and Neutral Complexes, *Organometallics*, **2016**, *35*, 595–604. d) Y. Wang, B. Ling, P. Liu and S. Bi, A Reaction Mechanism for Gold-Catalyzed Hydroamination/Cyclization of *o*-Phenylendiamine and Propargylic Alcohols. A DFT Study, *Organometallics*, **2018**, *37*, 3035–3044.

31 S. Grimme, Semiempirical hybrid density functional with perturbative second-order correlation, *J. Chem. Phys.*, **2006**, *124*, 034108.

32 a) A. D. Becke, Density-functional exchange-energy approximation with correct asymptotic behaviour, *Phys. Rev. A*, **1988**, *38*, 3098–3100. b) J. P. Perdew, Density-functional approximation for the correlation energy of the inhomogeneous electron gas, *Phys. Rev. B*, **1986**, *33*, 8822–8824.

33 F. Weigend and R. Ahlrichs, Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy, *Phys. Chem. Chem. Phys.*, **2005**, *7*, 3297–3305.

- 34 A. V. Marenich, C. J. Cramer and D. G. Truhlar, Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions, *J. Phys. Chem. B*, **2009**, *113*, 6378-6396.
- 35 Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, Gaussian, Inc., Wallingford CT, **2013**.
- 36 W. Yang and W. J. Mortier, The use of global and local molecular parameters for the analysis of the gas-phase basicity of amines, *J. Am. Chem. Soc.*, **1986**, *108*, 5708-5711.
- 37 F. M. Bickelhaupt and K. N. Houk, Analyzing Reaction Rates with the Distortion/Interaction-Activation Strain Model, *Angew. Chem. Int. Ed.* **2017**, *56*, 10070-10086.
- 38 Figure generated using CYLview: Cylview, 1.0b; Legault, C. Y., Université de Sherbrooke, **2009** (<http://www.cylview.org>).
- 39 V. Laserna and T. D. Sheppard, Gold Catalyzed Hydroamination of Propargylic Alcohols: Controlling Divergent Reaction Pathways to Access 1,3-Aminoalcohols, 3-Hydroxyketones or 3-Aminoketones. *ChemRxiv. Prepr.* **2018**, <https://doi.org/10.26434/chemrxiv.7160639.v1>.
- 40 B. M. Trost, W. M. Seganish, C. K. Chung and D. Amans, Total Synthesis of Laulimalide: Synthesis of the Northern and Southern Fragments. *Chem. Eur. J.*, **2012**, *18*, 2948-2960.
- 41 W. S. Johnson, T. M. Yarnell, R. F. Myers, D. R. Morton and S. G. Boots, Biomimetic polyene cyclizations. Participation of the (trimethylsilyl)acetylenic group and the total synthesis of the D-homosteroid system. *J. Org. Chem.*, **1980**, *45*, 1254-1259.
- 42 L. Mao, R. Bertermann, K. Emmert, K. J. Szabó and T. B. Marder, Synthesis of Vinyl-, Allyl-, and 2-Boryl Allylboronates via a Highly Selective Copper-Catalyzed Borylation of Propargylic Alcohols. *Org. Lett.* **2017**, *19*, 6586-6589.
- 43 M. Yoshida, M. Hayashi and K. Shishido, Palladium-Catalyzed Diastereoselective Coupling of Propargylic Oxiranes with Terminal Alkynes. *Org. Lett.* **2007**, *9*, 1643-1646.
- 44 W. Chen, J.-H. Tay, J. Ying, X.-Q. Yu and L. Pu, Catalytic Asymmetric Enyne Addition to Aldehydes and Rh(I)-Catalyzed Stereoselective Domino Pauson-Khand/[4 + 2] Cycloaddition. *J. Org. Chem.* **2013**, *78*, 2256-2265.

- 45 H. Chen, J. Zhang and D. Z. Wang, Gold-Catalyzed Rearrangement of Alkynyl Donor–Acceptor Cyclopropanes To Construct Highly Functionalized Alkylidenecyclopentenones. *Org. Lett.* **2015**, *17*, 2098–2101.
- 46 B. M. Trost and R. C. Livingston, An Atom-Economic and Selective Ruthenium-Catalyzed Redox Isomerization of Propargylic Alcohols. An Efficient Strategy for the Synthesis of Leukotrienes. *J. Am. Chem. Soc.* **2008**, *130*, 11970–11978.
- 47 S. S. Giri, L.-H. Lin, P. D. Jadhav and R.-S. Liu, Gold-Catalyzed 1,4-Carboxygenation of 3-En-1-ynamides with Allylic and Propargylic Alcohols via Non-Claisen Pathways. *Adv. Synth. Catal.* **2017**, *359*, 590–596.
- 48 J. Liu, Y. An, Y.-H. Wang, H.-Y. Jiang, Y.-H. Zhang and Z. Chen, Unprecedented Consecutive, Competitive Nucleophilic Addition to Construct Densely Functionalized Propargylic Alcohols. *Chem. Eur. J.* **2008**, *14*, 9131–9134.
- 49 H. Zhang, H. Tanimoto, T. Morimoto, Y. Nishiyama and K. Kakiuchi, Regioselective Rapid Synthesis of Fully Substituted 1,2,3-Triazoles Mediated by Propargyl Cations. *Org. Lett.* **2013**, *15*, 5222–5225.
- 50 D. V. Vidhani, M. E. Krafft and I. V. Alabugin, Rh(I)-Catalyzed Transformation of Propargyl Vinyl Ethers into (E,Z)-Dienals: Stereoelectronic Role of trans Effect in a Metal-Mediated Pericyclic Process and a Shift from Homogeneous to Heterogeneous Catalysis During a One-Pot Reaction. *J. Org. Chem.* **2014**, *79*, 352–364.
- 51 W. Yan, Q. Wang, Y. Chen, J. L. Petersen and X. Shi, Iron-Catalyzed C–O Bond Activation for the Synthesis of Propargyl-1,2,3-triazoles and 1,1-Bis-triazoles. *Org. Lett.* **2010**, *12*, 3308–3311.
- 52 G. Bartoli, C. Cimarrelli, E. Marcantoni, G. Palmieri and M. Petrini, Chemo- and Diastereoselective Reduction of β -Enamino Esters: A Convenient Synthesis of Both *cis*- and *trans*- χ -Amino Alcohols and β -Amino Esters. *J. Org. Chem.* **1994**, *59*, 5328–5335.
- 53 V. R. Chintareddy, K. Wadhwa and J. G. Verkade, $P(\text{PhCH}_2\text{NCH}_2\text{CH}_2)_3\text{N}$ Catalysis of Mukaiyama Aldol Reactions of Aliphatic, Aromatic, and Heterocyclic Aldehydes and Trifluoromethyl Phenyl Ketone. *J. Org. Chem.* **2009**, *74*, 8118–8132.
- 54 E. Hasegawa, K. Ishiyama, T. Kato, T. Horaguchi and T. Shimizu, Photochemically and thermally induced free-radical reactions of α , β -epoxy ketones with tributyltin hydride: selective C α -O bond cleavage of oxiranylmethyl radicals derived from α , β -epoxy ketones. *J. Org. Chem.* **1992**, *57*, 5352–5359.
- 55 S. E. Denmark and R. A. Stavenger, The Chemistry of Trichlorosilyl Enolates. Aldol Addition Reactions of Methyl Ketones. *J. Am. Chem. Soc.* **2000**, *122*, 8837–8847.
- 56 S. E. Denmark and J. R. Heemstra Jr., Lewis Base Activation of Lewis Acids. Catalytic Enantioselective Addition of Silyl Enol Ethers of Achiral Methyl Ketones to Aldehydes. *Org. Lett.* **2003**, *5*, 2303–2306.
- 57 G. Bartoli, M. Bosco, E. Marcantoni, M. Massaccesi, S. Rinaldi and L. Sambri, A Highly Diastereoselective TiCl_4 -Mediated Reduction of β -Hydroxy Ketones with $\text{BH}_3\cdot\text{py}$ — A Very Efficient and General Synthesis of syn-1,3-Diols. *Eur. J. Org. Chem.* **2001**, 4679–4684.

58 M. Lenze and E. B. Bauer, Chemoselective, iron(II)-catalyzed oxidation of a variety of secondary alcohols over primary alcohols utilizing H₂O₂ as the oxidant. *Chem. Comm.* **2013**, 49, 5889-5891.

59 X.-J. Tang, Z.-L. Yan, W.-L. Chen, Y.-R. Gao, S. Mao, Y.-L. Zhang and Y.-Q. Wang, Aza-Michael reaction promoted by aqueous sodium carbonate solution. *Tetrahedron Lett.* **2013**, 54, 2669-2673.